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CHAPTER - I 
NOVEL DRUG DELIVERY SYSTEM (NDDS) 
Introduction 
1The basic goal of novel drug delivery systems is to achieve a steady state 
blood or tissue level that is therapeutically effective and non toxic for an extended 
period of time. 
 Conventional drug delivery involves the formulation of the drug into a suitable 
form, such as compressed tablet for oral administration or a solution for IV 
administration. These dosage forms have been found to have serious limitations in 
terms of higher doses required, lower effectiveness, toxicity& adverse effects. 
NDDS are being developed rapidly, so as to overcome the limitations of 
conventional drug delivery. 
2The method by which a drug is delivered can have a significant effect on its 
efficacy. Some drugs have an optimum concentration range within which maximum 
benefit is derived, and concentrations above or below this range can be toxic or 
produce no therapeutic benefit at all. On the other hand, the very slow progress in the 
efficacy of the treatment of severe diseases, has suggested a growing need for a 
multidisciplinary approach to the delivery of therapeutics to targets in tissues. From 
this, new ideas on controlling the pharmacokinetics, pharmacodynamics, non-specific 
toxicity, immunogenicity, biorecognition, and efficacy of drugs were generated. These 
new strategies, often called drug delivery systems (DDS), are based on 
interdisciplinary approaches that combine polymer science, pharmaceutics, 
bioconjugate chemistry, and molecular biology. 
To minimize drug degradation and loss, to prevent harmful side-effects and to 
increase drug bioavailability and the fraction of the drug accumulated in the required 
zone, various drug delivery and drug targeting systems are currently under 
development. Among drug carriers one can name soluble polymers, microparticles 
made of insoluble or biodegradable natural and synthetic polymers, microcapsules, 
cells, cell ghosts, lipoproteins, liposomes, and micelles. The carriers can be made 
slowly degradable, stimuli-reactive (e.g., pH- or temperature-sensitive), and even 
targeted (e.g., by conjugating them with specific antibodies against certain 
characteristic components of the area of interest). Targeting is the ability to direct the 
drug-loaded system to the site of interest. Two major mechanisms can be 
distinguished for addressing the desired sites for drug release: (i) passive and (ii) 
active targeting. An example of passive targeting is the preferential accumulation of 
chemotherapeutic agents in solid tumors as a result of the enhanced vascular 
permeability of tumor tissues compared with healthy tissue. A strategy that could 
allow active targeting involves the surface functionalization of drug carriers with 
ligands that are selectively recognized by receptors on the surface of the cells of 
interest. Since ligand–receptor interactions can be highly selective, this could allow a 
more precise targeting of the site of interest. 
Controlled drug release and subsequent biodegradation are important for 
developing successful formulations. Potential release mechanisms involve: (i) 
desorption of surface-bound /adsorbed drugs; (ii) diffusion through the carrier matrix; 
(iii) diffusion (in the case of nanocapsules) through the carrier wall; (iv) carrier matrix 
erosion; and (v) a combined erosion /diffusion process. The mode of delivery can be 
the difference between a drug’s success and failure, as the choice of a drug is often 
influenced by the way the medicine is administered. Sustained (or continuous) release 
of a drug involves polymers that release the drug at a controlled rate due to diffusion 
out of the polymer or by degradation of the polymer over time. Pulsatile release is 
often the preferred method of drug delivery, as it closely mimics the way by which the 
body naturally produces hormones such as insulin. It is achieved by using drug-
carrying polymers that respond to specific stimuli (e.g., exposure to light, changes in 
pH or temperature).  
For over 20 years, researchers have appreciated the potential benefits of 
nanotechnology in providing vast improvements in drug delivery and drug targeting. 
Improving delivery techniques that minimize toxicity and improve efficacy offers 
great potential benefits to patients, and opens up new markets for pharmaceutical and 
drug delivery companies. Other approaches to drug delivery are focused on crossing 
particular physical barriers, such as the blood brain barrier, in order to better target the 
drug and improve its effectiveness; or on finding alternative and acceptable routes for 
the delivery of protein drugs other than via the gastro-intestinal tract, where 
degradation can occur. 
3Therapeutic Benefits on Novel drug delivery systems over conventional 
dosage forms. 
¾ Increased efficacy of the drug. 
¾ Site specific delivery. 
¾ Decreased toxicity / side effects. 
¾ Increased convenience. 
¾ Shorter hospitalisaiton. 
¾ Viable treatments for previously incurable diseases. 
¾ Potential for prophylactic application. 
¾ Lower health care costs- both short & long term. 
¾ Better patient compliance. 
2Drug Delivery Carriers 
Colloidal drug carrier systems such as micellar solutions, vesicle and liquid 
crystal dispersions, as well as nanoparticle dispersions consisting of small particles of 
10–400 nm diameter show great promise as drug delivery systems(fig a). When 
developing these formulations, the goal is to obtain systems with optimized drug 
loading and release properties, long shelf-life and low toxicity. The incorporated drug 
participates in the microstructure of the system, and may even influence it due to 
molecular interactions, especially if the drug possesses amphiphilic and/or mesogenic 
properties 
 Micelles formed by self-assembly of amphiphilic block copolymers (5-50 nm) 
in aqueous solutions are of great interest for drug delivery applications. The drugs can 
be physically entrapped in the core of block copolymer micelles and transported at 
concentrations that can exceed their intrinsic water- solubility. 
 
 Liposomes are a form of vesicles that consist either of many, few or just one 
phospholipid bilayers. The polar character of the liposomal core enables polar drug 
molecules to be encapsulated. Amphiphilic and lipophilic molecules are solubilized 
within the phospholipid bilayer according to their affinity towards the phospholipids. 
Participation of nonionic surfactants instead of phospholipids in the bilayer formation 
results in niosomes. 
Comparison of niosomes Vs liposomes: 
a)Niosomes are now widely studied as an alternative to liposomes, which exhibit 
certain disadvantages such as –they are expensive, their ingredients like phospholipids 
are chemically unstable because of their predisposition to oxidative degradation, they 
require special storage and handling and purity of natural phospholipids is variable.  
b) Differences in characteristics exist between liposomes and niosomes, especially 
since niosomes are prepared from uncharged single-chain surfactant and cholesterol 
whereas liposomes are prepared from double-chain phospholipids. Handjani-Vila et al 
were first to report the formation of vesicular system on hydration of mixture of 
cholesterol and a single-alkyl chain non-ionic surfactant.  
c) Niosomes behave in-vivo like liposomes, prolonging the circulation of entrapped 
drug and altering its organ distribution and metabolic stability. Encapsulation of 
various anti neoplastic agents in these carrier vesicles has been shown to decrease 
drug induced toxic side effects, while maintaining, or in some instances, increasing 
the anti-tumor efficacy. Such vesicular drug carrier systems alter the plasma clearance 
kinetics, tissue distribution, metabolism and cellular interaction of the drug. They can 
be expected to target the drug to its desired site of action and/or to control its release.  
d) As with liposomes, the properties of niosomes depends both on the composition of 
the bilayer and on method of their production. The intercalation of cholesterol in the 
bilayers decreases the entrapment volume during formulation and thus entrapment 
efficiency. As the concentration of cholesterol increases, entrapment efficiency 
decreases.  
e) The entrapment efficiency increases with increase in the concentration and 
lipophilicity of surfactant. Chandraprakash et al made Methotrexate loaded non-ionic 
surfactant vesicles using lipophilic surfactants like Span 40, Span 60 and Span 80 and 
found that Span 60 (HLB = 4.7) gave highest percent entrapment while Span 85 (HLB 
= 9.8) gave least entrapment. They also observed that as HLB value of surfactant 
decreased, the mean size was reduced.  
 
FIG a: Pharmaceutical carriers 
 
Dendrimers are nanometer-sized, highly branched and monodisperse 
macromolecules with symmetrical architecture. They consist of a central core, 
branching units and terminal functional groups. 
Nanoparticles (including nanospheres and nanocapsules of size 10-200 nm) 
are in the solid state and are either amorphous or crystalline. They are able to adsorb 
and/or encapsulate a drug, thus protecting it against chemical and enzymatic 
degradation. 
 Hydrogels are three-dimensional, hydrophilic, polymeric networks capable of 
imbibing large amounts of water or biological fluids. The networks are composed of 
homopolymers or copolymers, and are insoluble due to the presence of chemical 
crosslinks (tie-points, junctions), or physical crosslinks, such as entanglements or 
crystallites. 
 The ultimate goal in controlled release is the development of a microfabricated 
device with the ability to store and release multiple chemical substances on demand. 
Recent advances in microelectro-mechanical systems (MEMS) have provided a 
unique opportunity to fabricate miniature biomedical devices for a variety of 
applications ranging from implantable drug delivery systems to lab-on-a-chip devices. 
The controlled release microchip has the following advantages: (i) multiple chemicals 
in any form (e.g., solid, liquid or gel) can be stored inside and released from the 
microchip, (ii) the release of chemicals is initiated by the disintegration of the barrier 
membrane via the application of an electric potential, (iii) a variety of highly potent 
drugs can potentially be delivered accurately and in a safe manner, (iv) complex 
release patterns (e.g., simultaneous constant and pulsatile release) can be achieved, (v) 
the microchip can be made small enough to make local chemical delivery possible 
thus achieving high concentrations of drug at the site where it is needed while keeping 
the systemic concentration of the drug at a low level and (vi) water penetration into 
the reservoirs is avoided by the barrier membrane and thus the stability of protein-
based drugs with limited shelf-life is enhanced. 
Future Opportunities and Challenges 
 Nanoparticles and nanoformulations have already been applied as drug 
delivery systems with great success; and nanoparticulate drug delivery systems have 
still greater potential for many applications, including anti-tumour therapy, gene 
therapy, AIDS therapy, radiotherapy, in the delivery of proteins, antibiotics, 
virostatics, vaccines and as vesicles to pass the blood-brain barrier.  
Nanoparticles provide massive advantages regarding drug targeting, delivery 
and release and, with their additional potential to combine diagnosis and therapy, 
emerge as one of the major tools in nanomedicine. The main goals are to improve 
their stability in the biological environment, to mediate the bio-distribution of active 
compounds, improve drug loading, targeting, transport, release, and interaction with 
biological barriers. The cytotoxicity of nanoparticles or their degradation products 
remains a major problem, and improvements in biocompatibility obviously are a main 
concern of future research. 
There are many technological challenges to be met, in developing the following 
techniques: 
• Nano-drug delivery systems that deliver large but highly localized quantities 
of drugs to specific areas to be released in controlled ways;  
• Controllable release profiles, especially for sensitive drugs;  
• Materials for nanoparticles that are biocompatible and biodegradable;  
• Architectures / structures, such as biomimetic polymers, nanotubes;  
• Technologies for self-assembly;  
• Functions (active drug targeting, on-command delivery, intelligent drug 
release devices/ bioresponsive triggered systems, self-regulated delivery 
systems, systems interacting with the body, smart delivery);  
• Virus-like systems for intracellular delivery;  
• Nanoparticles to improve devices such as implantable devices/nanochips for 
nanoparticle release, or multi reservoir drug delivery-chips;  
• Nanoparticles for tissue engineering; e.g. for the delivery of cytokines to 
control cellular growth and differentiation, and stimulate regeneration; or for 
coating implants with nanoparticles in biodegradable polymer layers for 
sustained release; 
• Advanced polymeric carriers for the delivery of therapeutic peptide/proteins 
(biopharmaceutics), 
And also in the development of: 
• Combined therapy and medical imaging, for example, nanoparticles for 
diagnosis and manipulation during surgery (e.g. thermotherapy with magnetic 
particles);  
• Universal formulation schemes that can be used as intravenous, intramuscular 
or peroral drugs  
• Cell and gene targeting systems. 
TARGETED DRUG DELIVERY SYSTEM (TDDS) 
5Drug targeting is a phenomenon which maneunivers the distribution of drug in 
the body in such a manner that the major fraction of the drug interacts exclusively with 
the target tissue at a cellular or subcellular level. The objective of drug targeting is to 
achieve a desired pharmacological response at a selected site without undesirable 
interactions at other sites. 
This is especially important in cancer chemotherapy and enzyme replacement 
treatment. Drug targeting is the delivery of drugs to receptors or organs or any other 
specific part of the body to which one wishes to deliver the drug exclusively. 
The targeted or site specific delivery of drugs is indeed a very attractive goal 
because this provides one of the most potential ways to improve the therapeutic index 
of the drugs. 
Earlier work done between late 1960s and the mid 1980s stressed the need for 
drug carrier systems primarily to alter the pharmacokinetics of the already proven 
drugs whose efficacy might be improved by altering the rates for metabolism in liver 
or clearance by the kidneys. These approaches generally were not focussed to achieve 
site specific or targeted delivery such as getting a cytotoxic drug to cancerous tissue 
while sparing other normal, though equally sensitive tissue. With the advancement in 
the carrier technology the issue of delivering either individual drug molecule or the 
entire carrier to the desired site has been addressed during the last few years. 
A number of technological advances have since been made in the area of 
parenteral drug delivery leading to the development of sophisticated systems that 
allow drug targeting and the sustained or controlled release of parenteral medicines. 
6At present, drug targeting is achieved by one or two approaches. The first 
approach involves chemical modification of the parent compound to a derivative 
which is activated only at the target site. 
The second approach utilizes carriers such as liposomes, microspheres, nano 
particles, antibodies, cellular carriers (erythrocytes and lymphocytes) and 
macromolecules to direct drug to its site of action. 
Recent advancements have led to the development of several novel drug 
delivery system that could revolutionize the method of medication and provides a 
number of therapeutic benefits. 
The goal of any drug delivery system is to provide a therapeutic amount of 
drug to the proper site in the body to achieve promptly, and then maintain, the desired 
drug constant. The ideal drug delivery system delivers drug at a rate dictated by the 
need of the body over the period of treatment and it channels the active entity solely 
to the site of action. At present no available drug delivery systems can achieve all 
these goals.   The targeted drug delivery system achieves the site specific delivery but 
is unable to control the release kinetics of drug in predictable manner. 
Paul Ehrlich in 1906, initiated the era of development for targeted delivery 
when he envisaged a drug delivery mechanism that would target drugs directly to 
diseased cells. 
7Number of carriers were utilised to carry drug at the target organ / tissue 
which include immunoglobulins, serum proteins, synthetic polymers, lipid vesicles 
(liposomes), microspheres, erythrocytes, reverse micells, niosomes, pharmacosomes 
etc. Amongst the various carriers, few drug carriers reached the stage of clinical trials 
where phospholipid vesicle show strong potential for effective drug delivery to the site 
of action. These carriers (liposomes) are biologically inert in nature, devoid of any 
antigenic, pyrogenic or allergic reactions and their components can be utilised as the 
component of biological membrane. Drugs incorporated in liposomes are not activated 
under physiological conditions and do not cause unfavourable side effects as well.  
8There are various techniques by which drug can be targeted include 
1. Nanoparticles. 
2. Niosomes. 
3. Resealed erythrocytes. 
4. Microspheres. 
5. Monoclonal antibodies. 
6. Liposomes. 
MERITS OF TDDS 
 Targeting of the drug molecule towards the tissue or organ reduces the toxicity to 
the normal tissues. 
 Increased bioavailability. 
 Improved treatment of chronic illness where symptoms break through occurs when 
the plasma level of the drug falls below the MEC. 
 The drug is protected from first pass metabolism and GI degradation. 
 Improved patient compliance can be achieved due to decrease in amount and 
frequency of doses administered.  
 Biocompatibility can be well achieved. 
 Maintenance of therapeutic action of the drug overnight.  
 Systemic and local side effects are successfully reduced due to the reduction in the 
total amount of the drug. 
 Magnetically controlled systems can be used for targeting the drug towards 
superficial tissues. 
 Economic savings can be claimed due to reduction of total amount of drug used. 
 
9LIMITATIONS OF TDDS  
 TDDS such as liposomes, resealed erythrocytes and platelets suffer serious 
stability problems. 
 Although monoclonal antibodies show very high degree of site specificity the 
selection and Isolation procedures are too tough.  
 If the particle size of TDDS is high, they may be rapidly cleared by RES. 
 Magnetically controlled TDDS sliows high specificity to superficially located 
ornnns and tissues but cannot be targeted to deep seated organs. 
 Monoclonal antibodies may sometimes can cause unwanted antigen - antibody 
reaction which leads to serious consequences. 
 Microspheres of particle size more than 50µg can lead to problem of thrombo-
embolism in general circulation. 
 Once administered the drug cannot be removed if an undesirable action is 
precipitated or if the drug is no longer needed. 
 Most of such systems are administered by subcutaneous or Intraperitoneal route. 
The vehicles polymer employed should be sterile, hydrogen free, non irritating, 
biocompatible and biodegradable into non toxic compounds within an appropriate 
time, preferably close to duration of action. 
 The products which tend to remain intact may become lodged at some sites. If this 
occur slow release of drug from dosage form leads to a high localised 
concentration of drug which causes local irritation. 
 Drugs having biological half life of 1 hr or less are difficult to formulate as 
controlled release formulation. The high rates of elimination of such drugs from 
the body need an extremely large maintenance dose which provides 8 - 12hrs of 
continous therapy. 
 As these products normally contain large amount of drug there is a possibility of 
unsafe over dosage if the product is improperly made. 
 If it is once administered it may be difficult to stop the therapy due to toxicity or 
any other reasons. 
APPLICATIONS OF TDDS 
a. Cells as carriers 
Red blood cells, leukocytes, lymphocytes and fibroblasts have all been used as 
potential delivery vehicles for drugs. They have an advantage of inherent 
biocompatibility, but they cannot cross barriers and cannot easily fuse with other 
cells. Erythrocytes have been, explored as possible carriers for Cytarabine and 
Adriamycin. 
Many of the more biocompatible polymers can be used as small soluble 
molecular drug carriers or they can be assembled as both soluble and particulate drug 
vehicles. Large amount of drugs or agents can be incorporated through non-covalent 
forces into there assembled polymers. These particulate system are best utilized as 
sustained release vehicles. 
Bovine albumin or bovine serum albumin and human serum albumin have 
been extensively investigated for target specific and sustained delivery of cancer 
chemotherapeutic agents. 
The intra peritoneal administration of microspheres sustained the drug release 
over a period of time. 
NIOSOMES AS NOVEL DRUG DELIVERY CARRIER10 
Definition 
Niosomes are non-ionic surfactant vesicles obtained on hydration of synthetic 
nonionic surfactants, with or without incorporation of cholesterol or other lipids. They 
are vesicular systems similar to liposomes that can be used as carriers of amphiphilic 
and lipophilic drugs. Niosomes are promising vehicle for drug delivery and being 
non-ionic, it is less toxic and improves the therapeutic index of drug by restricting its 
action to target cells.  
Introduction 
At present no available drug delivery system achieves the site specific delivery 
with controlled release kinetics of drug in predictable manner.  
Paul Ehrlich, in 1909, initiated the era of development for targeted delivery when he 
envisaged a drug delivery mechanism that would target directly to diseased cell. Since 
then, number of carriers were utilized to carry drug at the target organ/tissue, which 
include immunoglobulins, serum proteins, synthetic polymers, liposomes, 
microspheres, erythrocytes, niosomes etc.  
Among different carriers liposomes and niosomes are well documented drug 
delivery.  
Drug targeting can be defined as the ability to direct a therapeutic agent 
specifically to desired site of action with little or no interaction with nontarget tissue.  
Niosomes or non-ionic surfactant vesicles are microscopic lamellar structures 
formed on admixture of non-ionic surfactant of the alkyl or dialkyl polyglycerol ether 
class and cholesterol with subsequent hydration in aqueous media.  
In niosomes, the vesicles forming amphiphile is a non-ionic surfactant such as 
Span – 60 which is usually stabilized by addition of cholesterol and small amount of 
anionic surfactant such as dicetyl phosphate.  
Schematic representation of a drug targeting through its linkage to niosome via 
antibody is shown below (fig b).  
Fig b: Niosome and antibody linkage 
 
Advantages of niosomes: 
The first report of non-ionic surfactant vesicles came from the cosmetic 
applications devised by L’Oreal.  
The application of vesicular (lipid vesicles and non-ionic surfactant vesicles) systems 
in cosmetics and for therapeutic purpose may offer several advantages: -  
¾ The vesicle suspension is water–based vehicle. This offers high patient 
compliance in comparison with oily dosage forms.  
¾ They possess an infrastructure consisting of hydrophilic, amphiphilic and 
lipophilic moieties together and as a result can accommodate drug molecules 
with a wide range of solubilities.  
¾ The characteristics of the vesicle formulation are variable and controllable. 
Altering vesicle composition, size, lamellarity, tapped volume, surface charge 
and concentration can control the vesicle characteristics.  
¾ The vesicles may act as a depot, releasing the drug in a controlled manner.  
Other advantages of niosomes include:  
¾ They are osmotically active and stable, as well as they increase the stability of 
entrapped drug.  
¾ Handling and storage of surfactants requires no special conditions.  
¾ They improve oral bioavailability of poorly absorbed drugs and enhance skin 
penetration of drugs.  
¾ They can be made to reach the site of action by oral, parenteral as well as 
topical routes.  
¾ The surfactants are biodegradable, biocompatible and non-immunogenic.  
¾ They improve the therapeutic performance of the drug molecules by delayed 
clearance from the circulation, protecting the drug from biological 
environment and restricting effects to target cells.  
¾ Niosomal dispersion in an aqueous phase can be emulsified in a non-aqueous 
phase to regulate the delivery rate of drug and administer normal vesicle in 
external non-aqueous phase.  
Method of preparation 
A. Ether injection method  
This method provides a means of making niosomes by slowly introducing a 
solution of surfactant dissolved in diethyl ether into warm water maintained at 60°C. 
The surfactant mixture in ether is injected through 14-gauge needle into an aqueous 
solution of material. Vaporization of ether leads to formation of single layered 
vesicles. Depending upon the conditions used, the diameter of the vesicle range from 
50 to 1000 nm.  
B. Hand shaking method (Thin film hydration technique) 
The mixture of vesicles forming ingredients like surfactant and cholesterol are 
dissolved in a volatile organic solvent (diethyl ether, chloroform or methanol) in a 
round bottom flask. The organic solvent is removed at room temperature (20°C) using 
rotary evaporator leaving a thin layer of solid mixture deposited on the wall of the 
flask. The dried surfactant film can be rehydrated with aqueous phase at 0-60°C with 
gentle agitation. This process forms typical multilamellar niosomes.  
Thermosensitive niosomes were prepared by Raja Naresh et al /i>(15) by evaporating 
the organic solvent at 60°C and leaving a thin film of lipid on the wall of rotary flash 
evaporator. The aqueous phase containing drug was added slowly with intermittent 
shaking of flask at room temperature followed by sonication.  
C. Sonication 
A typical method of production of the vesicles is by sonication of solution as 
described by Cable. In this method an aliquot of drug solution in buffer is added to the 
surfactant/cholesterol mixture in a 10-ml glass vial. The mixture is probe sonicated at 
60°C for 3 minutes using a sonicator with a titanium probe to yield niosomes.  
D. Micro fluidization 
Micro fluidization is a recent technique used to prepare unilamellar vesicles of 
defined size distribution. This method is based on submerged jet principle in which 
two fluidized streams interact at ultra high velocities, in precisely defined micro 
channels within the interaction chamber. The impingement of thin liquid sheet along a 
common front is arranged such that the energy supplied to the system remains within 
the area of niosomes formation. The result is a greater uniformity, smaller size and 
better reproducibility of niosomes formed.  
E. Multiple membrane extrusion method  
Mixture of surfactant, cholesterol and dicetyl phosphate in chloroform is made 
into thin film by evaporation. The film is hydrated with aqueous drug polycarbonate 
membranes, solution and the resultant suspension extruded through  which are placed 
in series for upto 8 passages. It is a good method for controlling niosome size.  
F. Reverse Phase Evaporation Technique (REV)  
Cholesterol and surfactant (1:1) are dissolved in a mixture of ether and 
chloroform. An aqueous phase containing drug is added to this and the resulting two 
phases are sonicated at 4-5°C. The clear gel formed is further sonicated after the 
addition of a small amount of phosphate buffered saline (PBS). The organic phase is 
removed at 40°C under low pressure. The resulting viscous niosome suspension is 
diluted with PBS and heated on a water bath at 60°C for 10 min to yield niosomes.  
G. Trans membrane pH gradient (inside acidic) Drug Uptake Process (remote 
Loading)  
Surfactant and cholesterol are dissolved in chloroform. The solvent is then 
evaporated under reduced pressure to get a thin film on the wall of the round bottom 
flask. The film is hydrated with 300 mM citric acid (pH 4.0) by vortex mixing. The 
multilamellar vesicles are frozen and thawed 3 times and later sonicated. To this 
niosomal suspension, aqueous solution containing 10 mg/ml of drug is added and 
vortexed. The pH of the sample is then raised to 7.0-7.2 with 1M disodium phosphate. 
This mixture is later heated at 60°C for 10 minutes to give niosomes.  
H. The “Bubble” Method 
It is novel technique for the one step preparation of liposomes and niosomes 
without the use of organic solvents. The bubbling unit consists of round-bottomed 
flask with three necks positioned in water bath to control the temperature. Water-
cooled reflux and thermometer is positioned in the first and second neck and nitrogen 
supply through the third neck. Cholesterol and surfactant are dispersed together in this 
buffer (pH 7.4) at 70°C, the dispersion mixed for 15 seconds with high shear 
homogenizer and immediately afterwards “bubbled” at 70°C using nitrogen gas.  
I. Formation of niosomes from proniosomes  
Another method of producing niosomes is to coat a water-soluble carrier such 
as sorbitol with surfactant. The result of the coating process is a dry formulation. In 
which each water-soluble particle is covered with a thin film of dry surfactant (fig c). 
This preparation is termed “Proniosomes”. The niosomes are recognized by the 
addition of aqueous phase at T > Tm and brief agitation.  
T=Temperature. 
Tm = mean phase transition temperature.  
Fig c: Niosome from proniosome  
 
Separation of Unentrapped Drug 
The removal of unentrapped solute from the vesicles can be accomplished by 
various techniques, which include: -  
 
1. Dialysis  
The aqueous niosomal dispersion is dialyzed in a dialysis tubing against 
phosphate buffer or normal saline or glucose solution.  
2. Gel Filtration  
The unentrapped drug is removed by gel filtration of niosomal dispersion 
through a Sephadex-G-50 column and elution with phosphate buffered saline or 
normal saline.  
3. Centrifugation  
The niosomal suspension is centrifuged and the supernatant is separated. The 
pellet is washed and then resuspended to obtain a niosomal suspension free from 
unentrapped drug.  
Characterization of niosomes 
a) Entrapment efficiency 
After preparing niosomal dispersion, unentrapped drug is separated by 
dialysis, centrifugation, or gel filtration as described above and the drug remained 
entrapped in niosomes is determined by complete vesicle disruption using 50% n-
propanol or 0.1% Triton X-100 and analysing the resultant solution by appropriate 
assay method for the drug. Where,  
Entrapment efficiency (EF) = (Amount entrapped total amount) x 100  
b) Vesicle diameter 
Niosomes, similar to liposomes, assume spherical shape and so their diameter 
can be determined using light microscopy, photon correlation microscopy and freeze 
fracture electron microscopy.  
Freeze thawing (keeping vesicles suspension at –20°C for 24 hrs and then 
heating to ambient temperature) of niosomes increases the vesicle diameter, which 
might be attributed to fusion of vesicles during the cycle.  
c) In-vitro release 
A method of in-vitro release rate study includes the use of dialysis tubing. A 
dialysis sac is washed and soaked in distilled water. The vesicle suspension is pipetted 
into a bag made up of the tubing and sealed. The bag containing the vesicles is placed 
in 200 ml of buffer solution in a 250 ml beaker with constant shaking at 25°C or 
37°C. At various time intervals, the buffer is analyzed for the drug content by an 
appropriate assay method.  
Factors affecting vesicles size, entrapment efficiency and release characteristics 
a)   Drug 
Entrapment of drug in niosomes increases vesicle size, probably by interaction 
of solute with surfactant head groups, increasing the charge and mutual repulsion of 
the surfactant bilayers, thereby increasing vesicle size. In polyoxyethylene glycol 
(PEG) coated vesicles, some drug is entrapped in the long PEG chains, thus reducing 
the tendency to increase the size. The hydrophilic lipophilic balance of the drug 
affects degree of entrapment.  
b)   Amount and type of surfactant 
The mean size of niosomes increases proportionally with increase in the HLB 
of surfactants like Span 85 (HLB 1.8) to Span 20 (HLB 8.6) because the surface free 
energy decreases with an increase in hydrophobicity of surfactant.  
The bilayers of the vesicles are either in the so-called liquid state or in gel state, 
depending on the temperature, the type of lipid or surfactant and the presence of other 
components such as cholesterol. In the gel state, alkyl chains are present in a well-
ordered structure, and in the liquid state, the structure of the bilayers is more 
disordered. The surfactants and lipids are characterized by the gel-liquid phase 
transition temperature (TC).  Phase transition temperature (TC) of surfactant also 
effects entrapment efficiency i.e. Span 60 having higher TC, provides better 
entrapment.  
c)   Cholesterol content and charge 
Inclusion of cholesterol in niosomes increases its hydrodynamic diameter and 
entrapment efficiency. In general, the action of cholesterol is two folds; on one hand, 
cholesterol increases the chain order of liquid-state bilayers and on the other, 
cholesterol decreases the chain order of gel state bilayers. At a high cholesterol 
concentration, the gel state is transformed to a liquid-ordered phase.  
An increase in cholesterol content of the bilayers resulted in a decrease in the 
release rate of encapsulated material and therefore an increase of the rigidity of the 
bilayers obtained. Presence of charge tends to increase the interlamellar distance 
between successive bilayers in multilamellar vesicle structure and leads to greater 
overall entrapped volume.  
d)   Methods of preparation 
Methods of preparation of niosomes such as hand shaking, ether injection and 
sonication in which Hand shaking method forms vesicles with greater diameter (0.35-
13nm) compared to the ether injection method (50-1000nm).  
Small sized niosomes can be produced by Reverse Phase Evaporation (REV) 
method .Microfluidization method gives greater uniformity and small size vesicles. 
Niosomes by trans membrane pH gradient (inside acidic) drug uptake process. 
Niosomes obtained by this method showed greater entrapment efficiency and better 
retention of drug.  
e)    Resistance to osmotic stress 
Addition of a hypertonic salt solution to a suspension of niosomes brings 
about reduction in diameter. In hypotonic salt solution, there is initial slow release 
with slight swelling of vesicles probably due to inhibition of eluting fluid from 
vesicles, followed by faster release, which may be due to mechanical loosening of 
vesicles structure under osmotic stress.  
Niosomes as drug carriers 
Niosomes containing anti-cancer drugs, if suitably designed, will be expected 
to accumulate within tumors in a similar manner to liposomes. The niosomal 
encapsulation of Methotrexate and Doxorubicin increases drug delivery to the tumor 
and tumoricidal activity of the drug.  
Doxorubicin niosomes possessing muramic acid and triglycerol surfaces were 
not taken up significantly by liver. The triglycerol niosomes accumulated in the tumor 
and muramic acid vesicles accumulated in the spleen. Those vesicles with 
polyoxyethylene surface were rapidly taken up by the liver and accumulated to a 
lesser extent in tumor.  
Applications 
Niosomal drug delivery is potentially applicable to many pharmacological 
agents for their action against various diseases. Some of their therapeutic applications 
are discussed below.  
1) Targeting of bioactive agents 
a) To reticulo-endothelial system (RES) 
The cells of RES preferentially take up the vesicles. The uptake of niosomes 
by the cells is also by circulating serum factors known as opsonins, which mark them 
for clearance. Such localized drug accumulation has, however, been exploited in 
treatment of animal tumors known to metastasize to the liver and spleen and in 
parasitic infestation of liver.  
b) To organs other than RES 
It has been suggested that carrier system can be directed to specific sites in the 
body by use of antibodies. Immunoglobulins seem to bind quite readily to the lipid 
surface, thus offering a convenient means for targeting of drug carrier (37). Many cells 
possess the intrinsic ability to recognize and bind particular carbohydrate 
determinants and this can be exploited to direct carriers system to particular cells.  
2) Neoplasia 
Doxorubicin, the anthracyclic antibiotic with broad spectrum anti tumor 
activity, shows a dose dependant irreversible cardio toxic effect. Niosomal delivery of 
this drug to mice bearing S-180 tumor increased their life span and decreased the rate 
of proliferation of sarcoma. Niosomal entrapment increased the half-life of the drug, 
prolonged its circulation and altered its metabolism. Intravenous administration of 
methotrexate entrapped in niosomes to S-180 tumor bearing mice resulted in total 
regression of tumor and also higher plasma level and slower elimination.  
3) Leishmaniasis 
Niosomes can be used for targeting of drug in the treatment of diseases in 
which the infecting organism resides in the organ of reticulo-endothelial system. 
Leishmaniasis is such a disease in which parasite invades cells of liver and spleen. 
The commonly prescribed drugs are antimonials, which are related to arsenic, and at 
high concentration they damage the heart, liver and kidney.  
4) Delivery of peptide drugs 
Oral delivery of 9-desglycinamide, 8-arginine vasopressin entrapped in 
niosomes in an in-vitro intestinal loop model and reported that stability of peptide 
increased significantly.  
5) Immunological application of niosomes 
Niosomes have been used for studying the nature of the immune response 
provoked by antigens. Niosomes as potent adjuvant in terms of immunological 
selectivity, low toxicity and stability.  
6) Niosomes as carriers for Hemoglobin. 
Niosomes can be used as a carrier for hemoglobin. Niosomal suspension 
shows a visible spectrum superimposable onto that of free hemoglobin. Vesicles are 
permeable to oxygen and hemoglobin dissociation curve can be modified similarly to 
non-encapsulated hemoglobin.  
7) Transdermal delivery of drugs by niosomes 
Slow penetration of drug through skin is the major drawback of transdermal 
route of delivery. An increase in the penetration rate has been achieved by 
transdermal delivery of drug incorporated in niosomes. Topical delivery of 
erythromycin from various formulations including niosomes or hairless mouse. From 
the studies, and confocal microscopy, it was seen that non-ionic vesicles could be 
formulated to target pilosebaceous glands.  
8) Other Applications 
a) Sustained Release 
The role of liver as a depot for methotrexate after niosomes are taken up by the 
liver cells. Sustained release action of niosomes can be applied to drugs with low 
therapeutic index and low water solubility since those could be maintained in the 
circulation via niosomal encapsulation.  
b) Localized Drug Action 
Drug delivery through niosomes is one of the approaches to achieve localized 
drug action, since their size and low penetrability through epithelium and connective 
tissue keeps the drug localized at the site of administration.  
Localized drug action results in enhancement of efficacy of potency of the 
drug and at the same time reduces its systemic toxic effects e.g. Antimonials 
encapsulated within niosomes are taken up by mononuclear cells resulting in 
localization of drug, increase in potency and hence decrease both in dose and toxicity.  
Asthma 
Asthma is an inflammatory disorder of the airways, which causes attacks of 
wheezing, shortness of breath, chest tightness, and coughing. 
Asthma is caused by inflammation in the airways. When an asthma attack 
occurs, the muscles surrounding the airways become tight and the lining of the air 
passages swell. This reduces the amount of air that can pass by, and can lead to 
wheezing sounds. Most people with asthma have wheezing attacks separated by 
symptom-free periods. Some patients have long-term shortness of breath with 
episodes of increased shortness of breath. Still, in others, a cough may be the main 
symptom. Asthma attacks can last minutes to days and can become dangerous if the 
airflow becomes severely restricted. 
In sensitive individuals, asthma symptoms can be triggered by breathing in 
allergy-causing substances (called allergens or triggers). Triggers include pet dander, 
dust mites, cockroach allergens, molds, or pollens. Asthma symptoms can also be 
triggered by respiratory infections, exercise, cold air, tobacco smoke and other 
pollutants, stress, food, or drug allergies. Aspirin and other non-steroidal anti-
inflammatory medications (NSAIDS) provoke asthma in some patients. 
Asthma is thought to be increasing in prevalence in India and in other 
developing countries. Current estimates suggest that, although prevalence varies by 
age group and location, 5% of the Indian population – or approximately 50 million 
people – have the disease. The situation is similar in other developing countries; 
overall, the World Health Organization estimates that 300 million people worldwide 
suffer from asthma. 
 
Exams and Tests 
Allergy testing may be helpful in identifying allergens in patients with 
persistent asthma. Common allergens include pet dander, dust mites, cockroach 
allergens, molds, and pollens. Common respiratory irritants include tobacco smoke, 
pollution, and fumes from burning wood or gas. 
The doctor will use a stethoscope to listen to the lungs. Asthma-related sounds 
may be heard. However, lung sounds are usually normal between asthma episodes. 
Tests may include: 
Lung function tests  
• Peak flow measurements  
• Chest x-ray  
• Blood tests, including eosinophil count (a type of white blood cell)  
 
Symptoms 
• Wheezing  
o Usually begins suddenly  
o Comes in episodes  
o May be worse at night or in early morning  
o Gets worse with cold aira, exercise, and heartburn (reflux)  
o May go away on its own  
o Is relieved by bronchodilators (drugs that open the airways)  
• Cough with or without sputum (phlegm) production  
• Shortness of breath that gets worse with exercise or activity  
• Intercostal retractions (pulling of the skin between the ribs when breathing)  
Emergency symptoms: 
• Extreme difficulty breathing  
• Bluish color to the lips and face  
• Severe anxiety due to shortness of breath  
• Rapid pulse  
• Sweating  
• Decreased level of alertness, such as severe drowsiness or confusion, during 
an asthma attack  
Additional symptoms that may be associated with this disease: 
• Nasal flaring  
• Chest pain  
• Tightness in the chest  
• Abnormal breathing pattern --breathing out takes more than twice as long as 
breathing in  
• Breathing temporarily stops  
Treatment  
Treatment is aimed at avoiding known allergens and respiratory irritants and 
controlling symptoms and airway inflammation through medication. 
There are two basic kinds of medication for the treatment of asthma: 
Long-term control medications are used on a regular basis to prevent attacks, not for 
treatment during an attack. Types include: 
• Inhaled steroids prevent inflammation  
• Leukotriene inhibitors  
• Anti-IgE therapy, a medicine given by injection to patients with more severe 
asthma  
• Long-acting bronchodilators help open airways  
• Cromolyn sodium or nedocromil sodium  
• Aminophylline or theophylline (not used as frequently as in the past)  
Sometimes a combination of steroids and bronchodilators are used, using either 
separate inhalers or a single inhaler. 
Quick relief, or rescue, medications are used to relieve symptoms during an attack. 
These include: 
• Short-acting bronchodilators (inhalers), such as Proventil, Ventolin, Xopenex, 
and thers.  
• Corticosteroids, such as prednisone or methylprednisolone given by mouth or 
into a vein  
Persons with mild asthma (infrequent attacks) may use quick relief medication as 
needed. Those with persistent asthma should take control medications on a regular 
basis to prevent symptoms. A severe asthma attack requires a medical evaluation and 
may require a hospital stay, oxygen, and intravenous medications. 
A peak flow meter, a simple device to measure lung volume, can be used at home 
to help you "see an attack coming" and take the appropriate action, sometimes even 
before any symptoms appear. If you are not monitoring asthma on a regular basis, an 
attack can take you by surprise. 
Peak flow measurements can help show when medication is needed, or other 
action needs to be taken. Peak flow values of 50-80% of an individual’s personal best 
results indicate a moderate asthma attack, while values below 50% indicate a severe 
attack. 
Prevention 
Asthma symptoms can be substantially reduced by avoiding known allergens 
and respiratory irritants. If someone with asthma is sensitive to dust mites, exposure 
can be reduced by encasing mattresses and pillows in allergen-impermeable covers, 
removing carpets from bedrooms, and by vacuuming regularly. Exposure to dust 
mites and mold can be reduced by lowering indoor humidity. 
If a person is allergic to an animal that cannot be removed from the home, the 
animal should be kept out of the patient's bedroom. Filtering material can be placed 
over the heating outlets to trap animal dander. Exposure to cigarette smoke, air 
pollution, industrial dusts, and irritating fumes should also be avoided. 
CHAPTER - II 
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12Majid Tabbakhian et al., investigated whether topical application of finasteride-
containing vesicles (liposomes and niosomes) could enhance drug concentration at the 
PSU, as compared to finasteride hydroalcoholic solution (HA). Liposomes consisted 
of phospholipid (dimyristoyl phosphatidylcholine (DMPC) or egg lecithin): 
cholesterol: dicetylphosphate  (8:2:1, mole ratio). Niosomes were comprising non-
ionic surfactant (polyoxyethylene alkyl ethers (Brij® series) or sorbitan 
monopalmitate):cholesterol: dicetylphosphate (7:3:1, mole ratio). Vesicles were 
prepared by the film hydration technique and characterized with regard to the size, 
drug entrapment efficiency and gel–liquid transition temperature (Tc). In vitro 
permeation of 3H-finasteride through hamster flank skinwas faster from 
hydroalcoholic solution (0.13 _g/cm2 h) compared to vesicles (0.025–0.058 _g/cm2 
h). In vivo deposition of 3H-finasteride vesicles in hamster ear showed that liquid-
state vesicle, i.e. those made of DMPC or Brij97:Brij76 (1:1), were able to deposit 2.1 
or 2.3% of the applied dose to the PSU, respectively. This was significantly higher 
than drug deposition by gel-state vesicles (0.35–0.51%) or HA (0.76%). Both in vitro 
permeation and in vivo deposition studies, demonstrated the potentials of liquid-state 
liposomes and niosomes for successful delivery of finasteride to the PSU. 
 
13Tianqing Liu, Rong Guo investigated the microstructure and transformation of the 
niosome prepared from PEG 6000/Tween 80/Span 80/H2O lamellar liquid crystal 
(LLC) are studied by the methods of freeze fracture-TEM, negative-staining TEM, 
dynamic light scattering technique and micropolarity measurements. The size of the 
niosome made from the LLC is little larger than that from directly mixing samples. 
The layer membrane of the former niosome is looser than that of the later niosome. 
The former niosome is held with the partial behaviors of the LLC and can tend to be 
transformed into the later niosome. 
 
14Abbas Pardakhty et al., studied niosomes of polyoxyethylene alkyl ethers 
(BrijTM) `prepared for encapsulation of insulin by film hydration method. Without 
cholesterol, brij 35 and brij 58 did not form niosomes, apparently because of relatively 
large polar head groups in comparison with their alkyl chains. The size of vesicles 
depended on the cholesterol content, charge incorporation or hydrophilicity of 
surfactants. Entrapment of insulin in bilayer structure of niosomes protected it against 
proteolytic activity of α-chymotrypsin, trypsin and pepsin in vitro. The maximum 
protection activity was seen in brij 92/cholesterol (7:3 molar ratios) in which only 
26.3 ± 3.98 percent of entrapped insulin was released during 24 h in simulated 
intestinal fluid (SIF). The kinetic of drug release for most formulations could be best 
described by Baker and Lonsdale equation indicating diffusion based delivery 
mechanism. These results indicate that niosomes could be developed as sustained 
release oral dosage forms for delivery of peptides and proteins such as insulin.  
 
15Tianqing Liu et al., investigated the structural behaviors of Hemoglobin (Hb) in 
detail by the methods of UV–vis and fluorescence spectra, circular dichroism, 
negative staining-TEM, FF-TEM and electrochemistry techniques in PEG 
6000/Tween 80/Span 80/H2O niosome system. The obtained results show that Hb can 
be adsorbed and outspread on the surface of the niosome membrane. The intensities of 
the UV–vis and fluorescence spectra of Hb in Hb/niosome system are greater than 
those in Hb/H2O system. The structure behaviors of Hb are partially stabilized and 
protected in Hb/niosome system. With the increase of PEG 6000 content in the 
niosome system, the content of helix structure decreases but the contents of β-sheet 
and random increase for Hb. The content of β -turn structure is almost independent of 
PEG 6000 content. The negative zeta potential of Hb and the conductivity of the 
system all decrease. The zeta potential of the niosome firstly decreases and then 
increases. 
 
16Agnishwar Girigoswami et al., investigated that Niosomal vesicles are more stable 
than liposomal vesicles due to higher chemical stability of surfactants compared to 
phospholipids. Niosomes have been prepared from Span20, Span80, Tween20 and 
Tween80. Fluorescence resonance energy transfer studies have been performed in 
these systems to determine donor–acceptor distances. It has been found that the 
fluorescence resonance energy transfer efficiency is better in niosomes compared to 
micelles. The formation of niosomes is guided by the hydrophile–lipophile balance 
value of the nonionic surfactant. 
 
 
17CP Jain et al., prepared Niosomes (nonionic surfactant-based vesicles) containing 
rifampicin using various nonionic surfactants of sorbitan ester class and cholesterol in 
50:50 percent mol fraction ratio. The drug-entrapped vesicles were characterized for 
their shape, size, drug entrapment efficiency and in vitro release rate. On the basis of 
in vitro characterization, the niosomes showing maximum entrapment and minimum 
release rate were selected for in vivo performance evaluation. Cumulative percent 
doses of rifampicin recovered in thoracic lymph following intravenous and 
intraperitoneal administrations of free rifampicin solution and niosome-encapsulated 
rifampicin were compared. The study revealed that effective compartmentalisation of 
the drug took place in the lymphatic system following intraperitoneal administration 
of niosome-encapsulated rifampicin. Thus rifampicin encapsulated in niosomes could 
successfully be used for treatment of tuberculosis along lymphatic system . 
 
18Deepika Aggarwal et al., formulated Chitosan (REVTMbio1) or Carbopol 
(REVTMbio2 and 3) coated niosomal timolol maleate (0.25%) formulations by 
reverse phase evaporation (REV) and compared to timolol solution (TMS; 0.25%) in 
terms of in vitro release and IOP lowering pharmacodynamic effect. The in vitro 
release phase of timolol (91% release in 2 h) was extended significantly by its 
incorporation into niosomes and further by the polymer coating (40–43% release upto 
10 h). The developed formulations were evaluated for their pharmacodynamics in 
albino rabbits, by measuring intraocular pressure (IOP) using a non-contact 
pneumatonometer, and were compared to a marketed in situ gel forming solution of 
timolol (Timolet GFS, 0.5%; Sun Pharma). REVTMbio1 formulation showed a more 
sustained effect of upto 8 h (vis a vis 6 h for carbopol-coated niosomes). TMS in 
comparison showed effect for only 2 h though the peak effect was slightly more 
(14%). Lowering of IOP in the contralateral eye (20–40% as compared to 100% in 
case of TMS), considerably reduces with REV and REVbio formulations indicating 
lesser systemic side effects. Moreover, the results of REVTMbio1formulation 
containing 0.25% of timolol maleate compared well with the 0.5% marketed gel 
formulation, indicating our formulation to be significantly better considering that 
similar effect is obtained at half the concentration. The later becomes especially 
important in context to the cardiovascular side effects associated with ocular timolol 
maleate therapy. 
 
19Rita Muzzalupo et al., described the formation of two niosomal systems based on 
synthetic bolaform surfactants (4, 7, 10, 13-pentaoxa-16-aza-cyclooctadecane) - 
hexadecanedioc acid diamide (BD-16) and α, ω-(4,7,10,13-pentaoxa-16-aza-
cyclooctadecane)-hexadecane (BC-16). Systems containing BD-16 or BC-16 and 
different amount of cholesterol (CH) were prepared by aqueous dispersion of films, 
followed by examination of methylene blue (MB) entrapment, particle size and 
morphology. Indeed, we also studied the hydration in the distilled water and 
physiological solution, in order to investigate the complexing ability on vesicle 
formation. The results obtained in this study show a high encapsulation capacity and 
this ability and the size depends on cholesterol content. 
 
20Ahmed S. Guinedi et al., investigated that Niosomes have been reported as a 
possible approach to improve the low corneal penetration and bioavailability 
characteristics shown by conventional ophthalmic vehicles. Niosomes formed from 
Span 40 or Span 60 and cholesterol in the molar ratios of 7:4, 7:6 and 7:7 were 
prepared using reverse-phase evaporation and thin film hydration methods. The 
prepared systems were characterized for entrapment efficiency, size, shape and in 
vitro drug release. Stability studies were carried out to investigate the leaching of drug 
from niosomes during storage. The intraocular pressure (IOP) lowering activity of 
acetazolamide Niosomal formulations in rabbits was measured using ShiØtz 
tonometer. Histological examination for the corneal tissues of rabbits receiving 
niosomal formulations was carried out for assessment of the ocular irritancy of 
niosomes. The results showed that the type of surfactant, cholesterol content and the 
method of preparation altered the entrapment efficiency and drug release rate from 
niosomes. Higher entrapment efficiencywas obtained with multilamellar niosomes 
prepared from Span 60 and cholesterol in a 7:6 molar ratio. Niosomal formulations 
have shown a fairly high retention of acetazolamide inside the vesicles (approximately 
75%) at a refrigerated temperature up to a period of 3 months. Each of the tested 
acetazolamide niosomes prepared by either method produced a significant decrease in 
IOP compared to the solution of free drug and plain niosomes. Multilamellar 
acetazolamide niosomes formulated with Span 60 and cholesterol in a 7:4 molar ratio 
were found to be the most effective and showed prolonged decrease in IOP. 
Histological examination of corneal tissues after instillation of niosomal formulation 
for 40 days showed slight irritation in the substantia propria of the eye which is 
reversible and no major changes in tissues were observed. 
 
21M. Manconi et al., studied the recently reported parametrization based on the 
differential geometry and the thermodynamics of dispersed systems to ascertain the 
capability of decylpolyglucoside alone or in association with cholesterol to form 
vesicle structures (niosomes). The theoretical calculation of the energy balance 
involved in the vesicles formation was carried out using values of the critical 
concentration of formation (ccf), surface tension and the molar surface area of the 
non-ionic surfactant. Furthermore, in order to confirm the theoretical results found in 
this work, we prepared and characterized vesicles made with decylpolyglucoside and 
cholesterol. The vesicles were characterized using transmission electron microscopy 
and dynamic light scattering. 
 
22Behrooz Nasseri investigated the mechanical characteristics of non-ionic bilayer 
membranes composed of sorbitan monostearate, cholesterol and poly-24- oxyethylene 
cholesteryl were studied by measuring the modulus of surface elasticity (µ), a measure 
of membrane strength, as a function of cholesterol content and temperature. The 
modulus of surface elasticity increased slowly with increasing cholesterol 
concentration, with a sharp increase around 40 mol% cholesterol (on average an 
increment of 0.43×106 Nm−2 per molar percentage), and displayed a maximum of 
6.5×106 Nm−2 around 47.5 mol% cholesterol. Further cholesterol resulted in a 
decrease in µ. Generally the interaction of cholesterol with the sorbitan monostearate 
should increase the rigidity of the membrane. However, the latter effect may be due to 
the formation of cholesterol clusters at high cholesterol content where excess amounts 
of cholesterol cannot interact with the sorbitan monostearate, and deposits on the 
bilayers compromising their uniformity, strength and permeability. This behaviour 
was evident when measurements were carried out above and below 25oC. 
 
23Suna Erdogan et al., studied about some accepted imaging techniques in clinic but 
most of them have several disadvantages limiting their effective use. Because of this, 
researchers are still performed to develop a rapid, specific means of detecting and/or 
imaging venous thrombi-based on the changing composition of the thrombus. 
Urokinase, fibrinolytic enzyme isolated form human urine, is a direct activator of 
plasminogen. In thrombus formation, plasminogen seems to be trapped in or absorbed 
onto fibrin matrix thus leading to a localised concentration of plasminogen. This 
suggests that radiolabelled urokinase would be a suitable compound for the detection 
of thrombi. The most important disadvantage of this enzyme is short plasma half life. 
To overcome this problem, it was decided to encapsulate the enzyme in drug delivery 
systems such as liposomes, niosomes or sphingosomes. In this study, we prepared, 
characterized and monitored the biodistribution of three types of vesicular systems 
containing urokinase. All types of prepared vesicles show in vitro an acceptable 
encapsulation, stability and release profile. Thrombus uptake was increased by 
encapsulation of urokinase into vesicles. 
 
24Prem N. Gupta et al., investigated the Non-invasive vaccine delivery which is a top 
priority for public health agencies because conventional immunization practices are 
unsafe and associated with numerous limitations. Recently, the skin has emerged as a 
potential alternative route for non-invasive delivery of vaccine. Topical immunization 
(TI), introduction of antigen through topical application onto the intact skin, has many 
practical merits compared to injectable routes of administration. One of the 
possibilities for increasing the penetration of bioactives through the skin is the use of 
vesicular systems. Specially designed lipid vesicles are attracting intense attention and 
can be used for non-invasive antigen delivery. In the present study, elastic vesicle 
transfersomes, non-ionic surfactant vesicles (niosomes) and liposomes were used to 
study their relative potential in non-invasive delivery of tetanus toxoid (TT). 
Transfersomes, niosomes and liposomes were prepared and characterized for shape, 
size and entrapment efficiency. These vesicles were extruded through polycarbonate 
filter (50-nm pore size) to assess the elasticity of the vesicles. The immune 
stimulating activity of transfersomes, niosomes and liposomes were studied by 
measuring the serum anti-TT IgG titre following topical immunization. The immune 
response elicited by topical immunization was compared with that elicited by same 
dose of alum-adsorbed tetanus toxoid (AATT) given intramuscularly. The results 
indicate that optimal formulations of transfersomes, niosomes and liposomes could 
entrap 72.7±3.4, 42.5±2.4 and 41.3±2.2% of antigen and their elasticity values were 
124.4±4.2, 29.3±2.4 and 21.7±1.9, respectively. In vivo study revealed that topically 
given TT containing transfersomes, after secondary immunization, could elicit 
immune response (anti-TT-IgG) that was equivalent to one that produced following 
intramuscularly alum-adsorbed TT-based immunization. In comparison to 
transfersomes, niosomes and liposomes elicited weaker immune response. Thus 
transfersomes hold promise for effective non-invasive topical delivery of antigen(s). 
 
25Ibrahim A. Alsarra et al., investigated the Permeation of a potent nonsteroidal anti-
inflammatory, ketorolac, across excised rabbit skin from various proniosome gel 
formulations was investigated using Franz diffusion cells. Each of the prepared 
proniosomes significantly improved drug permeation and reduced the lag time (P < 
.05). Proniosomes prepared with Span 60 provided a higher ketorolac flux across the 
skin than did those prepared with Tween 20 (7- and 4-fold the control, respectively). 
A change in the cholesterol content did not affect the efficiency of the proniosomes, 
and the reduction in the lecithin content did not significantly decrease the flux (P 
<0.05). The encapsulation efficiency and size of niosomal vesicles formed by 
proniosome hydration were also characterized by specific high performance liquid 
chromatography method and scanning electron microscopy. Each of the prepared 
niosomes achieved about 99% drug encapsulation. Vesicle size was markedly 
dependent on the composition of the proniosomal formulations. Proniosomes may be 
a promising carrier for ketorolac and other drugs, especially due to their simple 
production and facile up.  
 
26Christine Dufesa et al., evaluated the glucose-bearing niosomes as a brain targeted 
delivery system for the vasoactive intestinal peptide (VIP). To this end, VIP/125I-VIP-
loaded glucose-bearing niosomes were intravenously injected to mice. Brain uptake 
was determined by measuring the radioactivity of 125I-labeled VIP using γ-counting, 
after intravenous administration of VIP in solution or encapsulated in glucose-bearing 
niosomes or in control niosomes. VIP integrity was assessed by reversed-phase HPLC 
analysis of brain extracts. Distribution of 125I-VIP derived radioactivity was examined 
from serial brain slices. HPLC analysis confirmed the presence of intact VIP in brain 
after administration of VIP-loaded niosomes, but not after administration of VIP 
solution. Encapsulation within glucose-bearing niosomes mainly allowed a 
significantly higher VIP brain uptake compared to control niosomes (up to 86%, 5 
min after treatment). Brain distribution of intact VIP after injection of glucose-bearing 
niosomes, indicated that radioactivity was preferentially located in the posterior and 
the anterior parts of the brain, whereas it was homogeneously distributed in the whole 
brain after the administration of control vesicles. 
 
27D. Gopinath et al., investigated Ascorbyl palmitate (ASP) as bilayer vesicle 
forming material. It formed vesicles (Aspasomes) in combination with cholesterol and 
a negatively charged lipid (dicetyl phosphate). Aspasomes were prepared by film 
hydration method followed by sonication in which aqueous azidothymidine (AZT) 
solution was encapsulated in aqueous regions of bilayer. Aspasomes were obtained 
with all compositions containing 18–72 mol% cholesterol. Differential scanning 
calorimetric data of aspasome dispersion and anhydrous mixtures of ascorbyl 
palmitate, cholesterol and dicetyl phosphate confirm the formation of bilayered 
vesicles with ascorbyl palmitate. Cholesterol content in aspasome did not exhibit any 
relation with vesicle size, zeta potential or percent entrapment.A substantial change in 
release rate of azidothymidine from aspasome was noticed on varying the proportion 
of cholesterol. Release rate and cholesterol content in Aspasomes did not exhibit any 
relation. A preparation with 45 mol% of cholesterol showed maximum retardation in 
release rate, than other compositions. The change in capture volume with time 
(latency) was studied for 8 h and with such a short duration study it was difficult to 
predict long term stability of these vesicles. But release experiments do indicate 
stability upto 18 h. Percent reducing activity of aspasome was estimated by measuring 
the absorbance of α, α diphenyl-β-picrylhydrazyl (DPPH) at 517 nm after addition of 
test antioxidant samples. These studies revealed that the antioxidant potency of 
ascorbyl moiety is retained even after converting ascorbyl palmitate into vesicles 
(Aspasomes). The antioxidant potency of Aspasomes was assessed by measuring the 
protection offered by this preparation against quinolinic acid induced lipoperoxidation 
of whole human blood in vitro, where in the lipoperoxidation was monitored by 
measuring thiobarbituric acid reactive substances (TBARS) levels. Aspasome 
rendered much better antioxidant activity than ascorbic acid. Transdermal permeation 
of aspasomal AZT, ASP-AZT aqueous dispersion and AZT-solution across excised 
rat skin was investigated in vitro using Franz diffusion cell. Permeation of aspasomal 
AZT was much higher than the other two preparations. 
 
28Y. Perriea et al., compared to naked DNA immunisation, entrapment of plasmid-
based DNA vaccines into liposomes by the dehydration–rehydration method has 
shown to enhance both humoural and cell-mediated immune responses to encoded 
antigens administered by a variety of routes. In this paper we have compared the 
potency of lipid-based and non-ionic surfactant based vesicle carrier systems for DNA 
vaccines after subcutaneous immunisation. Plasmid pI.18Sfi/NP containing the 
nucleoprotein (NP) gene of A/Sichuan/2/87 (H3N2) influenza virus in the pI.18 
expression vector was incorporated by the dehydration–rehydration method into 
various vesicle formulations. The DRV method, entailing mixing of small unilamellar 
vesicles (SUV) with DNA, followed by dehydration and rehydration, yielded high 
DNA vaccine incorporation values (85–97% of the DNA used) in all formulations. 
Studies on vesicle size revealed lipid-based systems formed cationic submicron size 
vesicles whilst constructs containing a non-ionic surfactant had significantly large z-
average diameters (>1500 nm). Subcutaneous vesicle-mediated DNA immunisation 
employing two DRV(DNA) formulations as well as naked DNA revealed that 
humoural responses (immunoglobulin total IgG, and subclasses IgG1 and 1gG2a) 
engendered by the plasmid encoded nucleoprotein were substantially higher after 
dosing twice, 28 days apart with 10_g DRV-entrapped DNA compared to naked 
DNA. Comparison between the lipid and non-ionic based vesicle formulations 
revealed no significant difference in stimulated antibody production. These results 
suggest that, not only can DNA be effectively entrapped within a range of lipid and 
non-ionic based vesicle formulations using the DRV method but that such DRV 
vesicles containing DNA may be a useful system for subcutaneous delivery of DNA 
vaccines. 
 
29Maria Manconi  et al., compared the chemical stability of tretinoin (TRA) in 
methanol and in vesicular suspensions exposed both to UV and artificial daylight 
conditions with the aim of evaluating the potential of niosomes as topical carriers 
capable of improving the stability of photosensitive drugs. Tretinoin-loaded niosomes 
were prepared from polyoxyethylene (4) lauryl ether (Brij® 30), sorbitan esters 
(Span® 40 and Span® 60) and a commercial mixture of octyl/decyl polyglucosides 
(Triton® CG110). Liposomes made from hydrogenated (P90H) and non-
hydrogenated (P90) soy phosphatidylcholines were also prepared and studied. In order 
to evaluate the influence of vesicle structure on the photostability of tretinoin, TRA-
loaded vesicles were prepared by the film hydration method, extrusion technique and 
sonication. After UV irradiation, TRA dissolved in methanol degraded very quickly 
while the incorporation in vesicles always led to a reduction of the photodegradation 
process. The photoprotection offered by vesicles varied depending on the vesicle 
structure and composition. After fluorescent light irradiation for 21 days, not all the 
studied vesicular formulations improved TRA stability when compared with the free 
drug in methanol. Tretinoin incorporated in P90 or Span vesicles presented a half-life 
shorter or very close to that of the free drug. However, the inclusion of TRA in P90H 
liposomes and Brij® 30 or Triton® CG110 niosomes retarded the drug 
photodegradation. 
 
30Aranya Manosroi et al., prepared vesicles (niosomes) with hydrated mixture of 
various non-ionic surfactants and cholesterol was studied. The bilayer formation was 
characterized by X-cross formation under light polarization microscope and the ability 
of the vesicles to entrap water-soluble substance. Membrane rigidity was measured by 
means of mobility of fluorescence probe as a function of temperatures. The 
entrapment efficiencies of the vesicles and microviscosities of the vesicular 
membrane depended on alkyl chain length of non-ionic surfactants and amount of 
cholesterol used to prepare vesicles. The stearyl chain (C18) non-ionic surfactant 
vesicles showed higher entrapment efficiency than the lauryl chain (C12) non-ionic 
surfactant vesicles. Cholesterol was used to complete the hydrophobic moiety of 
single alkyl chain nonionic surfactants for vesicle formation. Niosome prepared with 
Tween 61 bearing a long alkyl chain and a large hydrophilic moiety in the 
combination with cholesterol at 1:1 molar ratio was found to have the highest 
entrapment efficiency of water soluble substances. 
 
31G. Redziniak investigated various approaches to intra- and percutaneous 
administration of drugs, e.g. application of patches, ointments, iontophoresis, 
electroporation, the use of lipid vesicles like liposomes and niosomes presents 
numerous advantages. They are not toxic or invasive, may deliver hydrophobic and/or 
hydrophilic molecules, and the size of the transported molecule is not a limiting 
factor. Liposomes are obtained with natural amphiphilic lipids whereas niosomes are 
composed of synthetic amphiphilic molecules. These microscopic vesicles contain 
from one to several concentric lipid bi-layers with intercalated aqueous compartments. 
Trans-epidermal penetration of the vesicles is proportional to the “fluidity” of their 
lipids and their negative charge. Several drugs and cosmetics in this gallenic form are 
already commercially available and successfully used, presenting a better dose/effect 
ratio and provoking less side- effects. 
 
32S Bhaskaran et al., formulated Niosomes containing salbutamol sulphate using 
different non-ionic surfactants like Tween 20, 40, 60, 80, Span 20, 40, 60, 80 and Brij 
35 by transmembrane pH gradient method. The drug encapsulation efficiency varied 
from 28 percent to 79 percent. The vesicles have been characterized by infrared 
spectroscopy. In vitro drug release studies were carried out using dialysis bag and 
phosphate buffer, pH 7.4 as a dissolution medium for 24 h. The formulation exhibited 
retarded release for 24 h and Span 60 was found to be the most satisfactory surfactant 
which released 78.4 percent of drug in 24 h. Particle size distribution studies were 
carried out be optical microscopy technique. Most of the niosomes were found to be 
spherical in shape. Thermal stability studies were carried out at 4 degree, 25 degree 
and 50 degree for one month. The product was lyophilized. Tissue distribution studies 
were carried out on rabbits. The maximum concentration was seen in lungs. 
 
33Yongmei Hao et al., prepared niosomes which have high encapsulation capacity for 
soluble drugs, starting from Span 60 and cholesterol, an improved method, 
evaporation-sonication method, was proposed. The corresponding niosomes show a 
good stability at least 40 days. Colchicine was chosen as a model drug for examining 
the capsulation capacity of these niosomes. To obtain the highest encapsulation 
efficiency, several factors including the structure of surfactant, level of lipid, content 
of drug and cholesterol were investigated and optimized. The inner cause was also 
discussed. The results indicate that the Span 60 is the most ideal surfactant among 
four kinds of Span. Furthermore, the release studies of colchicine and 5-fluorouracil 
(5-FU) in vitro from niosomes exhibited a prolonged release profile as studied over a 
period of 24 h. The results demonstrated that niosomes prepared in this way not only 
have high encapsulation capacity but also is expected that side effects of drugs may be 
reduced. It still suggests that this method may be used extensively in the field of 
encapsulation soluble drugs. 
 
34Tejas R. Desai et al., demonstrated the potential of encapsulating all-trans-retinoic 
acid (ATRA) in niosomes and delivering it as an inhaled aerosol. Niosomes may 
provide a means to reduce the toxicity of ATRA and alter the pharmacokinetics in a 
manner similar to liposomes. In addition, the low cost of the surfactants used for 
preparing niosomes and their greater stability compared with liposomes makes them 
an attractive alternative. Various nonionic surfactants were used to achieve optimum 
encapsulation and nebulization efficiencies, and the best formulations were obtained 
with combinations of (Span 20+Tween 80) and (Span 60+Tween 80) using an ATRA 
concentration of 1mg/ml. The aerosol produced with the selected niosomal 
formulations upon nebulization in PARI LC STAR nebulizers driven by a Pulmo-
Aide compressor was subsequently analyzed for the determination of size distribution 
and entrapment efficiencies on each stage of an Anderson cascade impactor operated 
in a manner that avoids spurious sizing due to droplet evaporation. Mass median 
aerodynamic diameters (MMADs) of 3.7±0.3 and 3.58±0.03 µm, geometric standard 
deviation (GSD) values of 1.59±0.17 and 1.51±0.01 and entrapment efficiencies well 
above 50% were obtained for the optimized formulations. The results are very 
encouraging and offer an alternative approach to the respiratory delivery of ATRA by 
aerosolization. 
 
35Maria Manconi et al., prepared Tretinoin-loaded niosomes from polyoxyethylene 
(4) lauryl ether, sorbitan esters and a commercial mixture of octyl/decyl 
polyglucosides, in the presence of cholesterol and dicetyl phosphate. Liposomes made 
of hydrogenated and non-hydrogenated phosphatidylcholine were also prepared as a 
comparison reference. A study was made of the influence of vesicle composition and 
preparation method on the vesicle structure (MLV, LUV, SUV), size distribution, 
entrapment efficiency and in vitro release of incorporated tretinoin. Results showed 
that in the presence of cholesterol all the amphiphiles used were able to form stable 
vesicle dispersions with or without tretinoin. Vesicle sizes were dependent on the 
preparation method, bilayer composition and drug load. Multilamellar (MLV) vesicles 
were larger than extruded (LUV) and sonicated (SUV) vesicles while drug-loaded 
vesicles were generally smaller than empty ones. Entrapment efficiencies of tretinoin 
were always very high especially for multilamellar (91–99%) and extruded (88–98%) 
vesicles. The in vitro release of tretinoin from the prepared vesicular formulations was 
studied using the vertical Franz diffusion cells. The rate of drug release through a 
Silastic membrane from a liposomal and niosomal tretinoin dispersion was generally 
faster than from a tretinoin solution. Release data showed that tretinoin delivery is 
mainly affected by the vesicular structure and that tretinoin delivery increased from 
MLVs to LUVs to SUVs. 
 
 
 
36Jia-You Fang et al., elucidated the skin permeation and partitioning of a fluorinated 
quinolone antibacterial agent, enoxacin, in liposomes and niosomes, after topical 
application. In vitro percutaneous absorption experiments were performed on nude 
mouse skin with Franz diffusion cells. The influence of vesicles on the 
physicochemical property and stability of the formulations were measured. The 
enhanced delivery across the skin of liposome and niosome encapsulated enoxacin 
had been observed after selecting the appropriate formulations. The optimized 
formulations could also reserve a large amount of enoxacin in the skin. A significant 
relationship between skin permeation and the cumulative amount of enoxacin in the 
skin was observed. Both permeation enhancer effect and direct vesicle fusion with 
stratum corneum may contribute to the permeation of enoxacin across skin. 
Formulation with niosomes demonstrated a higher stability after 48 h incubation 
compared to liposomes. The inclusion of cholesterol improved the stability of 
enoxacin liposomes according to the results from encapsulation and turbidity. 
However, adding negative charges reduced the stability of niosomes. The ability of 
liposomes and niosomes to modulate drug delivery without significant toxicity makes 
the two vesicles useful to formulate topical enoxacin. 
 
37R. Agarwal et al., studied dithranol in the topical treatment of psoriasis. However, 
the use of dithranol in psoriatic condition is inconvenient and troublesome, as it has 
irritating, burning, staining and necrotizing effect on the normal as well as the 
diseased skin. The entrapment of drug in vesicles is viewed to help in the localized 
delivery of the drug and an improved availability of the drug at the site will reduce the 
dose and in turn, the dose-dependent side effects like irritation and staining. The 
investigations deal with critical parameters controlling the formulation and 
stabilization of dithranol loaded liposomes and niosomes. The entrapment efficiency 
of dithranol in liposomes was optimized by altering the proportion of phosphatidyl 
choline and cholesterol, and in case of niosomes it was between Span 60 and 
cholesterol. Hydration and permeation mediums were also established keeping in 
view the poor solubility and stability of dithranol. The mean liposome and niosomes 
sizes were 4±1.25 and 5±1.5 µm, respectively. The drug-leakage study carried out at 
different temperatures of 4–8, 25±2 and 37 °C for a period of two months affirms that 
the drug leakage increased at a higher temperature. The in vitro permeation study 
using mouse abdominal skin shows significantly enhanced permeation with vesicles 
as indicated by flux of dithranol from liposomes (23.13µg/cm2/h) and niosomes 
(7.78µg/cm2/h) as compared with the cream base (4.10µg/cm2/h). 
 
38Gopi N. Devaraj et al., studied the monomers of some amphiphiles organize into 
bilayers to form liposomes and niosomes. Such bilayers are unstable or leaky and 
hence cholesterol is a common ingredient included to stabilize them. Cholesterol 
stabilizes bilayers, prevents leakiness, and retards permeation of solutes enclosed in 
the aqueous core of these vesicles. Other than cholesterol a material with good 
bilayer-stabilizing properties is yet to be identified. We have substituted cholesterol 
with fatty alcohols in niosomes containing polyglyceryl-3-diisostearate (PGDS) and 
polysorbate-80 (PS-80) to explore their membrane-stabilizing property via permeation 
studies. Niosomes of polyglyceryl-3-di-isostearate, fatty alcohol/cholesterol, and 
Polysorbate were prepared by ether injection method. Aqueous solution of ketorolac 
tromethamine (KT) was entrapped in them. The effects of alkyl chain length of fatty 
alcohols (C12, C14, C16, C18, and C16+18), of acyl chain length of polyoxyethylene 
sorbitan monoester surfactants, and of the molar ratio of lipid mixture on the release 
rate of ketorolac from niosomes were assessed by employing modified dissolution–
dialysis method. Niosomes with cholesterol or fatty alcohols have exhibited a 
common release pattern. Niosomes containing fatty alcohol showed a considerably 
slower release rate of KT than those containing cholesterol. Based on the release rate, 
fatty alcohols can be ranked as stearyl<myristyl<cetyl<lauryl<cetostearyl. In 
niosomes containing PGDS, myristyl alcohol (MA), and polysorbate, the fatty acid 
chain length of polyoxyethylene sorbitan ester-type surfactants has influenced the 
release rate and encapsulation efficiency. Based on the release rate, polysorbates can 
be ranked as polysorbate-20 (C12)<polysorbate-60 (C18)<polysorbate-80 
(C9=9)<polysorbate-40 (C16). In niosome preparation containing polysorbate-20 and 
dioctyl sodium sulfosuccinate (anionic surfactant), the release rate was slower than 
niosomes containing polysorbate-20. When MA concentration is kept constant at 50 
mole% and the ratio of PGDS and PS-80 was altered, significant changes in 
entrapment efficiency and the release rate were observed. However, this ratio did not 
exhibit any relation with encapsulation efficiency or release rate. The release rate and 
entrapment exhibited an inverse correlation (r 2 =0.8774 at p <0.02 for the data of 
molar ratios of PGDS:MA: PS80; r 2 =0.975 at p <0.001 for the data of acyl chain 
length variation of polysorbates). It can be concluded that stable niosomes of 
polyglyceryl-3-di-isostearate could be prepared with fatty alcohols and polysorbates 
instead of cholesterol and that the release of solutes from these niosomes can be 
optimized by altering membrane constituents and their concentrations. 
 
39P.Arunothayanun et al., investigated the effects of processing variables, 
particularly temperature and sonication, on the physical characteristics and phase 
transitional behaviour of two niosomal systems based on a hexadecyl diglycerol ether 
(C16G2) have been studied. Systems containing C16G2, cholesterol and poly-24-
oxyethylene cholesteryl ether (Solulan C24) in the molar ratios 91:0:9 and 49:49:2 
were prepared by aqueous dispersion of films, followed by examination of 5(6)-
carboxyfluorescein entrapment, particle size and morphology. The thermal behaviour 
was examined using high sensitivity differential scanning calorimetry (HSDSC) and 
hot stage microscopy, while the effects of sonication were studied in terms of size and 
morphology, both immediately after preparation and on storing for 1 h at room 
temperature and 60°C. Polyhedral niosomes were formed from systems containing 
C16G2 and Solulan C24 alone, while cholesterol-containing systems formed spherical 
vesicles mixed with tubular structures; the polyhedral systems were found to have a 
larger particle size and higher CF entrapment efficiency. HSDSC studies showed the 
polyhedral systems to exhibit an endotherm at 45.4°C and a corresponding exotherm 
at 39.1°C on cooling which were ascribed to a membrane phase transition; no 
equivalent transition was observed for the cholesterol containing systems. Hot stage 
microscopy showed the polyhedral vesicles to convert to spherical structures at 48°C, 
while on cooling the spherical vesicles split into smaller structures and reverted to the 
polyhedral shape at 49°C. Sonication resulted in the polyhedral vesicles forming 
spherical structures which underwent a particle size increase on storage at room 
temperature but not at 60°C. The study suggests that the polyhedral vesicles undergo a 
reversible transition to spherical vesicles on heating or sonication and that this 
morphological change may be associated with a membrane phase transition. 
 
40Calum J. Drummond et al., reviewed the new impetus in surfactant self-assembly 
objects as agents for drug delivery that are an alternative to micellar, 
lamellar/liposome, niosome and transfersome or microemulsion-based vehicles. The 
review focus herein is on the application of hexagonal, cubic, ‘intermediate’ (viz. 
rhombohedral, tetragonal and monoclinic) and L3 (‘sponge’).mesophases. 
 
41P. Arunothayanun et al., formulated formed Non-ionic surfactant vesicles 
(niosomes) using hexadecyl diglycerol ether (C16G2) and a series of polyoxyethylene 
alkyl ethers exhibit a variety of shapes dependant on their membrane composition. 
These surfactants form with an equimolar amount of cholesterol a mixture of largely 
spherical and tubular niosomes. In the absence of cholesterol, they form faceted 
polyhedral structures. The physicochemical and biological differences between 
polyhedral and spherical/tubular niosomes were studied. Polyhedral niosomes 
undergo a reversible shape transformation into spherical structures on heating above 
their phase transition temperature (Tm). The viscosity of polyhedral niosomes at room 
temperature is higher than their spherical counterparts due to their faceted and 
relatively rigid shape, and is more dependant on temperature due to shape 
transformation. At room temperature, polyhedral niosomes possess more rigid gel 
phase membranes and are less osmotically sensitive; however, they are more 
permeable because of a lack of or low levels of cholesterol in their membranes. 
Polyhedral niosomes loaded with luteinising hormone releasing hormone (LHRH), 
nonetheless, slow the release of drug compared to solution, albeit to a small extent. 
 
42S.P. Vyas et al., formed Nonionic surfactant vesicles using Span 60, cholesterol and 
dicetyl phosphate. The prepared multilamellar vesicles (MLVs) were coated by 
interfacial polymerization technique using p-phthaloyl dichloride and L-lysine. The 
formation of the polymeric coat was confirmed by optical microscopic and 
transmission electron microscopic studies. The prepared, plain and polymer-coated 
MLVs were studied for their size, shape, encapsulation efficiency, in vitro release 
profile and effect of osmotic shock on vesicle. The results observed showed that the 
polymer-coated MLVs were stable under various osmotic conditions. In vivo studies 
were carried out on albino rats. The half-life and area under curve were found to be 
high in the case of polymer-coated MLVs as compared to plain MLVs and plain drug 
solution. In vivo studies using inflamed rat model also indicated that the polymer-
coated MLVs were more stable and could release the drug in a controlled fashion as 
compared to plain MLVs. 
 
43Gopal K. Pillai  et al., prepared indomethacin incorporated in a non-ionic surfactant 
vesicle (niosome). The objective was to study the effect of niosomal-encapsulated 
indomethacin on platelet function such as inhibition of aggregation and ATP release 
induced by a variety of agonists (adenosine 5%-diphosphate (ADP), epinephrine, 
arachidonic acid, ristocetine) and to explore the feasibility of carrier-mediated drug 
delivery to the platelets. Multilamellar vesicles (niosomes) were prepared from 
Tween-60 by the lipid hydration method. Freshly prepared human platelet rich plasma 
(PRP) was used for aggregation:inhibition studies, the extent of which was observed 
as a change in light transmission measured by the Chronolog Aggregometer. The 
percent inhibition of aggregation induced by the agonist ADP ranged from 28.21±0.28 
at the 2.0 µmol level to 92.6±1.20 at 12.7 µmol of the encapsulated drug while the 
same concentrations of the drug inhibited aggregation only to the extent of 
13.75±0.13 and 36.82±0.57%, respectively. A 100% inhibition of aggregation induced 
by arachidonic acid was achieved by niosomal indomethacin while inhibition by the 
free drug was 41.9% at equimolar concentrations. ATP release study showed that 
100% inhibition was achieved by 8 µmol of the encapsulated drug while inhibition by 
the free drug was 40.00±1.82%. Therefore, at equimolar doses, the niosomal drug 
proved to be more efficient in inhibiting platelet aggregation than the free drug, 
probably due to greater quantity of the drug reaching the specific site of inhibition in 
the interior of the platelets and acting directly on the cyclo-oxygenase system to 
prevent thromboxane formation. 
 
44S.P. Vyas and N. Venkatesan formulated Nonionic surfactant vesicles using Span 
60, cholesterol and dicetyl phosphate. The prepared multilamellar vesicles (MLVs) 
were coated by interfacial polymerization technique using p-phthaloyl dichloride and 
L-lysine. The formation of the polymeric coat was confirmed by optical microscopic 
and transmission electron microscopic studies. The prepared, plain and polymer-
coated MLVs were studied for their size, shape, encapsulation efficiency, in vitro 
release profile and effect of osmotic shock on vesicle. The results observed showed 
that the polymer-coated MLVs were stable under various osmotic conditions. In vivo 
studies were carried out on albino rats. The half-life and area under curve were found 
to be high in the case of polymer-coated MLVs as compared to plain MLVs and plain 
drug solution. In vivo studies using inflammed rat model also indicated that the 
polymer-coated MLVs were more stable and could release the drug in a controlled 
fashion as compared to plain MLVs. 
 
 
 
45C.O. Rentel et al., developed a peroral vaccine delivery system based on non-ionic 
surfactant vesicles (niosomes) was evaluated using BALB/c mice. Ovalbumin was 
encapsulated in various lyophilized niosome preparations consisting of sucrose esters, 
cholesterol and dicetyl phosphate. Two different formulations were compared in this 
study. The specific antibody titres within serum, saliva and intestinal washings were 
monitored by ELISA on days 7, 14, 21 and 28 after intragastric administration. Only 
encapsulation of ovalbumin into Wasag®7 (70% stearate sucrose ester, 30% palmitate 
sucrose ester (40% mono-, 60% di:tri-ester)) niosomes resulted in a significant 
increase in antibody titres. Administration of ovalbumin and empty niosomes did not 
exert a similar effect; neither did administration of any control formulation. In 
contrast to ovalbumin loaded Wasag®7 niosomes, application of the more hydrophilic 
Wasag®15 (30% stearate sucrose ester, 70% palmitate sucrose ester (70% mono-, 
30% di/tri-ester)) niosome preparations did not result in an increase in antibody titres. 
 
46Sudaxshina Murdan et al., investigated multi-component organogels formed using 
the non-ionic surfactant sorbitan monostearate as gelator have been formulated to 
contain niosomes. The purpose of this study was to evaluate the potential of these 
vesicle-in-water-in-oil (v/w/o) gels as delivery vehicles for vaccines. Bovine serum 
albumin (BSA) and haemagglutinin (HA) were used as model antigens in depot and 
immunogenicity studies respectively. The complex gels were prepared by the addition 
of a hot (60oC) aqueous niosome suspension (v/w) to the sol phase (o, an organic 
solution of the gelator); a vesicle-in-water-in-oil (v/w/o) emulsion was produced 
which cools to an opaque, semi-solid, thermoreversible v/w/o gel. Light microscopy 
of the organogel revealed that the microstructure consists of a tubular network of 
surfactant aggregates in the organic medium, the niosome suspension being dispersed 
in these surfactant tubules. Therefore, in such gels, the vaccine is thought to be 
entrapped in the niosomes, themselves located within the sorbitan monostearate 
tubular network in the organic medium. In vivo, a depot effect was observed 
following intramuscular administration of the gel containing the entrapped bovine 
serum albumin, cleared from the injection site over a period of days. The relatively 
short-lived nature of the depot was thought to arise due to interactions between the gel 
and the local interstitial fluid which results in gel disintegration in situ. Thus, the 
niosomes containing antigens are believed to be released from the organic gel. 
Immunogenicity studies showed that the v/w/o gel as well as one of the controls, the 
water-in-oil (w/o) gel, possess immunoadjuvant properties and enhance the primary 
and secondary antibody titres (of total IgG, IgG1 , IgG2a and IgG2b ) to haemagglutinin 
antigen. As far as humoral immunity is concerned, the w/o gel showed stronger 
immunoadjuvant properties compared to the v/w/o gel, being effective at a lower 
antigen dose i.e 0.1µg HA. 
 
47Ijeoma F. Uchegbu et al., reviewed the self assembly of non-ionic surfactants into 
vesicles was first reported in the seventies by researchers in the cosmetic industry. 
Since then a number of groups world wide have studied non-ionic surfactant vesicles 
(niosomes) with a view to evaluating their potential as drug carriers. This article 
presents a summary of the achievements in the field to date. Niosomes may be formed 
form a diverse array of amphiphiles bearing sugar, polyoxyethylene, polyglycerol, 
crown ether and amino acid hydrophilic head groups and these amphiphiles typically 
possess one to two hydrophobic alkyl, perfluoroalkyl or steroidal groups. The self 
assembly of surfactants into niosomes is governed not only by the nature of the 
surfactant but by the presence of membrane additives, the nature of the drug 
encapsulated and the actual method of preparation. Methods of niosome preparation 
and the number of different morphologies that have been identified are detailed. The 
influence of formulation factors on niosome stability is also examined as are methods 
to optimise drug loading. In vivo these systems have been evaluated as immunological 
adjuvants, anti-cancer, anti-infective drug targeting agents and carriers of anti-
inflammatory drugs. Niosomes have also been used in diagnostic imaging. Efforts to 
achieve transdermal and ophthalmic drug delivery with some formulations are also 
discussed. 
 
48Bhavana Vora et al., formulated proniosome based transdermal drug delivery 
system of levonorgestrel (LN) was developed and extensively characterized both in 
vitro and in vivo. The proniosomal structure was liquid crystalline-compact niosomes 
hybrid which could be converted into niosomes upon hydration. The system was 
evaluated in vitro for drug loading, rate of hydration (spontaneity), vesicle size, 
polydispersity, entrapment efficiency and drug diffusion across rat skin. The effect of 
composition of formulation, amount of drug, type of Spans, alcohols and sonication 
time on transdermal permeation profile was observed. The stability studies were 
performed at 48C and at room temperature. The biological assay for progestational 
activity included endometrial assay and inhibition with the formation of corpora lutea. 
The study demonstrated the utility of proniosomal transdermal patch bearing 
levonorgestrel for effective contraception. 
 
49Ijeoma F. Uchegbu et al., investigated that PK1 is an N-(2-hydroxypropyl) 
methacrylamide (HPMA) copolymer-doxorubicin conjugate currently in early clinical 
development. Niosome encapsulation is a means to increase PK1 blood residence 
time, potentially promote tumour uptake and produce a slow, sustained release of 
active drug. Factors effecting encapsulation efficiency and size of PK1-niosome 
formulations were studied. Five surfactants were used to prepare PK1-niosomes; 
hexadecyl poly-5-oxyethylene ether (C16EO5); octadecyl poly-5-oxyethylene ether 
(C18EO5); hexadecyl diglycerol ether (C16G2); sorbitan monopalmitate (Span 40) and 
sorbitan monostearate (Span 60). All were mixed in equimolar ratio with cholesterol 
and varying amounts of Solulan C24 (a cholesteryl poly-24-oxyethylene ether) (9–39 
mol%). Dicetylphosphate (DCP) was also added (2 mol%). Passive association of 
PK1 with preformed C16G2 and Span 60 vesicles was low (3–4%) while subsequent 
dehydration (freeze drying) followed by rehydration of the formulation increased the 
entrapment to 61% in the C16G2 formulation. Transmission electron microscopy 
revealed that these niosomes had an electron dense core, evidence of intravesicular 
concentration of PK1. Increasing Solulan C24 content resulted in decreased PK1 
entrapment after freeze drying, and the vesicle size was also decreased. Solulan C24 
(39 mol%) caused pronounced vesicle aggregation on freeze drying, whereas at lower 
levels (9 mol%), PK1 appeared to act as a cryoptrotectant and the mean size of 
C16G2 niosomes was 235 nm. A PK1:surfactant:lipid ratio of 0.3 (11.2 mg ml -1 
doxorubicin) was achieved with Span 60 niosomes. This formulation, and the C16G2 
niosomes, did not induce red blood cell lysis at the proposed dose for in vivo use. 
Preliminary in vivo biodistribution studies showed PK1-C16G2 niosomes to be mainly 
taken up by the liver and spleen. After 24 h, 25 and 3% of dose administered was 
present as free doxorubicin in these organs respectively. 
 
50Jain CP et al., investigated Niosomes (non-ionic, surfactant-based vesicles) 
containing rifampicin of 8-15 microns in diameter were prepared using Span-85 and 
cholesterol in various molar fractions. The process variables that could affect the 
physical characteristics of niosomes and in vitro release of the drug from the niosomes 
were studied and optimized. In vivo distribution studies of the prepared niosomes 
found that 65% of the drug could be localized in the lungs by controlling the niosome 
size. 
 
51Toshimitsu Yoshioka et al., studied Formation of multilamellar vesicles (niosomes) 
of a series of sorbitan monoesters (span 20, 40, 60 and 80) and a sorbitan trioleate 
(Span 85) has been studied using a mechanical shaking technique without sonication. 
5(6)-carboxyfluorescein (CF) was used as a model solute to investigate entrapment 
efficacy and release. For Span 80, cholesterol and dicetyl phosphate (DCP) in the 
molar ratio 47.5:47.5:5.0, entrapment efficacy increased linearly with increasing 
concentration of lipid. Entrapment efficacy per mmol lipid, however, was constant at 
about 34%, independent of the lipid concentration. Entrapment efficacy increased 
with increasing cholesterol content when vesicles were prepared by changing the 
molar ratio of non-ionic surfactant to cholesterol. Most efficient entrapment of CF 
occurred with Span 60 (HLB 4.7). Mean size of the un-sonicated niosomes showed a 
regular increase with increasing HLB from Span 85 (HLB 1.8). the release rate of CF 
from vesicles depended on the surfactant used in the preparation of the vesicles. 
 
52K.S. Chandraprakash et al., prepared Methotrexate encapsulated in niosomes. The 
entrapment efficacy increased in lipophilicity of surfactant. Unilamellar vesicles 
prepared with span 60 showed maximum entrapment and its pharmacokinetics in mice 
transplanted with S-180 tumor was marketedly different in comparison to unentrapped 
Methotrexate. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER - III   
SALBUTAMOL 
 
 Structure  
  
 Overview  
1) Class  
a) This drug is a member of the following class(es):  
        - Beta-2 Adrenergic Agonist  
        - Bronchodilator  
        - Cardiovascular Agent  
        - Sympathomimetic  
Drug Properties  
A) Synonyms  
        - Albuterol  
        - Albuterol Sulf  
        - Albuterol Sulfate  
        - Salbutamol  
B) Physicochemical Properties  
1) Albuterol  
 
a) Molecular Weight  
1) 239.3  
b) Solubility  
1) Soluble in ethanol; sparingly soluble in water; very soluble in 
chloroform  
2) Albuterol Sulfate  
a) Molecular Weight  
1) 576.7  
b) pH  
1) Syrup: 3 to 4.5  
c) Solubility  
1) Soluble in water and slightly soluble in ethanol  
DRUG DOSING 
 Adult Dosage  
  Inhalation, oral  
  Metered-Dose Inhaler  
a) The recommended dose of albuterol sulfate is 2 inhalations by 
metered-dose inhaler every 4 to 6 hours as needed. One 
inhalation every 4 hours may be sufficient in some patients. 
Each actuation delivers 108 micrograms (mcg) of albuterol 
sulfate, equivalent to 90 mcg of albuterol base  
b) Alternatively, 1 to 2 inhalations (0.1 milligrams (mg) to 0.2 
mg) three to four times daily may be used for long-term 
treatment in adults, and 1 to 2 inhalations once to treat acute 
symptoms, up to a maximum of 12 inhalations daily. A 
minimum of 3 hours is required between doses  
Oral route  
Tablets and Syrup  
 a) The recommended initial dose of albuterol is 2 or 4 
milligrams (mg) orally 3 or 4 times daily. If a patient does not 
respond to the 4 mg dose, it may be carefully increased stepwise 
as tolerated, not to exceed 8 mg orally 4 times a day (32 mg total 
daily dose)  
Extended-Release Tablets  
 a) The recommended dose of extended-release albuterol sulfate 
tablets is 8 milligrams (mg) orally every 12 hours. In some 
patients, including those with low body weight, a dose of 4 mg 
orally every 12 hours may be started and increased to 8 mg 
every 12 hours  
Parenteral route  
Injection  
a) For the short-term treatment of severe bronchospasm in all 
types of bronchial asthma, the following dosing of albuterol is 
recommended for adults: one-half ampule (0.5 milliliter (mL) or 
0.25 milligram (mg)) by subcutaneous or intramuscular injection 
stat, may repeat in 15 minutes with one-half ampule if needed. 
This regimen may be administered every 4 hours (Fachinfo 
Salbulair(R)0.5, 1997).  
Infusion  
a) The recommended dose for intravenous administration of 
albuterol in adults (depending on body weight) for the short-
term treatment of severe bronchospasm in all types of bronchial 
asthma, is 0.2 mL to 0.4 mL (0.1 mg to 0.2 mg) albuterol 
infused slowly, this may be repeated in 15 minutes with up to 
twice the dose if necessary. The maximum recommended dose 
for single administration is 1 ampule (1 mL or 0.5 mg) 
(Fachinfo Salbulair(R)0.5, 1997).  
 
 
 
Pharmacokinetics  
Onset and Duration  
A) Onset  
1) Albuterol Sulfate  
a) Initial Response  
1) AEROSOL INHALATION: 5 to 15 minutes (Evans et al, 1971; 
Sillett et al, 1976); (Spector et al 1977)(Jenkinson et al, 1977; 
Walker et al, 1972).  
2) POWDER INHALATION: 10 minutes (Pullan & Martin, 1980).  
b) Peak Response  
1) AEROSOL INHALATION: 30 to 120 minutes  
2) NEBULIZER INHALATION: 60 TO 120 minutes  
3) INTERMITTENT POSITIVE PRESSURE BREATHING: 30 to 
120 minutes  
4) ORAL: 15 to 180 minutes.  
a) After 4 to 8 mg doses, or 0.15mg/kg  
5) SUBLINGUAL: 2 to 3 hours  
B) Duration  
1) Albuterol Sulfate  
a) Single Dose  
1) AEROSOL INHALATION: 4 to 6 hours 
2) ORAL IMMEDIATE RELEASE: 6 to 8 hours  
Drug Concentration Levels  
A) Albuterol Sulfate  
1) Therapeutic Drug Concentration  
a) Premature labor, 8 to 33 ng/mL  
 
2) Time to Peak Concentration  
a) Aerosol inhalation: 3 to 4 h  
b) Nebulized inhalation: 0.5 h  
c) Oral, extended-release tablet: 6 h  
d) Oral, inhalation: 0.42 h  
e) Oral, syrup: within 2 h  
f) Oral, tablet: 2 h to 2.6 h  
g) ORAL: 1 to 4 hours  
h) SUBLINGUAL: Regular release, 2 to 3 hours  
i) IPPB INHALATION: 2 to 4 hours  
j) AEROSOL INHALATION: 3 to 4 hours  
ADME  
Absorption  
A) Albuterol Sulfate  
1) Bioavailability  
a) Nebulized inhalation: less than 20%  
b) Oral, extended-release tablet: approximately 100% relative to 
immediate-release tablet  
c) Oral: 50% to 85%   
d) BUCCAL: Less than 20%  
e) IPPB INHALATION: 21.4% to 30.2%  
2) Effects of Food  
a) Extended-release tablet: food decreases rate of absorption 
without altering extent of bioavailability  
Distribution  
A) Distribution Sites  
1) Albuterol Sulfate  
a) Protein Binding  
1) 10%  
B) Distribution Kinetics  
1) Albuterol Sulfate  
a) Volume of Distribution  
1) 156 +/- 38 liters  
Metabolism  
A) Metabolites  
1) Albuterol Sulfate  
a) Active metabolite: 4-O-sulfate ester  
Excretion  
A) Kidney  
1) Albuterol Sulfate  
a) Renal Clearance (rate)  
1) 238 mL/min after intravenous administration (Hutchings et al, 
1987).  
b) Renal Excretion (%)  
1) Nebulized inhalation: most of absorbed dose  
2) Oral: 76% over 3 days  
3) 64% to 98%  
a)In pregnant patients, 18.7% of the drug was excreted 
unchanged after oral administration  
B) Feces  
1) Albuterol Sulfate  
a) 1.2% to 7% eliminated in feces from oral dose  
b) Oral: 4%  
C) Total Body Clearance  
1) Albuterol Sulfate  
a) Clearance: 480 +/- 123 mL/min  
b) Clearance: 501 +/- 185 mL/min pregnant patients  
Elimination Half-life  
A) Parent Compound  
1) Albuterol Sulfate  
a) Oral, extended-release tablet: 9.3 h  
b) Oral, inhalation: approximately 4.6 h to 5 h  
c) Oral, tablet and syrup: about 5 h to 7.2 h  
d) 3 to 6.5 hours  
Precautions  
A) Albuterol sulphate 
1) cardiovascular disorders, especially coronary insufficiency, cardiac 
arrhythmias, and hypertension; may produce clinically significant 
changes on pulse rate, blood pressure, symptoms, and/or 
electrocardiogram  
2) convulsive disorders  
3) diabetes mellitus  
4) hyperthyroidism  
5) hypokalemia  
Adverse Reactions  
 Nervousness  
 shakiness  
 dizziness 
 headache 
 uncontrollable shaking of a part of the body  
 muscle cramps 
 excessive motion or activity sudden changes in mood 
 nosebleed  
 nausea  
 increased or decreased appetite  
 difficulty falling asleep or staying asleep  
 pale skin 
  
 Symptoms of overdose may include:  
• seizures  
• chest pain  
• fast, irregular or pounding heartbeat  
• nervousness  
• headache  
• uncontrollable shaking of a part of the body  
• dry mouth  
• nausea  
• dizziness  
• excessive tiredness  
• lack of energy  
• difficulty falling asleep or staying asleep  
Marketed formulations 
• Ventmax SR  
• Volmax 
• Ventolin injection 
• Ventolin solution for Intravenous infusion  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER - IV 
POLYOXYETHYLENE SORBITAN FATTY ACID ESTERS11 
 
Functional Category 
Emulsifying agent; nonionic surfactant; solubilizing agent; wetting, 
dispersing/ suspending agent. 
 
Applications in Pharmaceutical Formulation or Technology 
Polyoxyethylene sorbitan fatty acid esters (polysorbates) are a series of partial 
fatty acid esters of sorbitol and its anhydrides copolymerized with approximately 20, 
5, or 4 moles of ethylene oxide for each mole of sorbitol and its anhydrides. The 
resulting product is therefore a mixture of molecules of varying sizes rather than a 
single uniform compound. Polysorbates containing 20 units of oxyethylene are 
hydrophilic nonionic surfactants that are used widely as emulsifying agents in the 
preparation of stable oil-in-water pharmaceutical emulsions. They may also be used as 
solubilizing agents for a variety of substances including essential oils and oil-soluble 
vitamins, and as wetting agents in the formulation of oral and parenteral suspensions. 
They have been found to be useful in improving the oral bioavailability of drug 
molecules that are substrates for p-glycoprotein. Polysorbates are also widely used in 
cosmetics and food products 
 
Stability and Storage Conditions 
Polysorbates are stable to electrolytes and weak acids and bases; gradual 
saponification occurs with strong acids and bases. The oleic acid esters are sensitive 
to oxidation. Polysorbates are hygroscopic and should be examined for water content 
prior to use and dried if necessary. Also, in common with other polyoxyethylene 
surfactants, prolonged storage can lead to the formation of peroxides.  
Polysorbates should be stored in a well-closed container, protected from light, 
in a cool, dry place. 
Uses of polysorbates 
Uses Concentration (%) 
Emulsifying agent - 
Used alone in oil-in-water emulsions 1–15 
Used in combination with hydrophilic 
emulsifiers in oil-in-water 
emulsions 
1–10 
Used to increase the water-holding 
properties of ointments 
1–10 
Solubilizing agent - 
For poorly soluble active constituents in 
lipophilic bases 
1–10 
Wetting agent - 
For insoluble active constituents in 
lipophilic bases 
0.1–3 
 
Incompatibilities 
Discoloration and/or precipitation occur with various substances, especially 
phenols, tannins, tars, and tar like materials. The antimicrobial activity of paraben 
preservatives is reduced in the presence of polysorbates 
Regulatory Status 
Polysorbates 60, 65, and 80 are GRAS listed. Polysorbates 20, 40, 60, 65, and 
80 are accepted as food additives in Europe. Polysorbates 20, 40, 60, and 80 are 
included in the FDA Inactive Ingredients Guide (IM, IV, oral, rectal, topical, and 
vaginal preparations). Polysorbates are included in parenteral and nonparenteral 
medicines licensed in the UK. Polysorbates 20, 21, 40, 60, 61, 65, 80, 81, 85, and 120 
are included in the Canadian List of Acceptable Non-medicinal Ingredients 
 
Tween 20 
 
Nonproprietary Names 
 Polysorbate 20 
Synonym 
 Armotan PML 20; Capmul POE-L; Campul POE-L Low PV; Crillet 1; 
Drewmulse; E432; Durfax 20; E432; Eumulgin SML; Glycosperse L-20;  Hodag 
PSML-20; Lamesorb SML-20; Liposorb L-20; Liposorb L-20K; Montanox 20; Nissan 
Nonion LT-221; Norfox Sorbo T-20; POE-SML; Ritabate 20; Sorbax PML-20; 
sorbitan monododecanoate; Sorgen TW-20; T-Maz 20; TMaz 20K; poly(oxy-1,2-
ethanediyl) derivatives; polyoxyethylene 20 laurate; Protasorb L-20; Tego SML 20; 
Tween 20. 
Chemical name 
 Polyoxyethylene 20 sorbitan monolaurate 
Structure 
 
 
 
 
Emprical formula and molecular weight 
 C58H114O26 
M.W: 1128 
Colour and form 
 Yellow oily liquid 
Solubility  
 Soluble in water and ethanol. Insoluble in mineral oils 
Safety 
Moderate toxicity by IP and IV routes. Moderately toxic by ingestion. Human 
skin irritant. 
· LD50 (hamster, oral): 18 g/kg 
· LD50 (mouse, IV): 1.42 g/kg 
· LD50 (rat, oral): 37 g/kg 
 
 
 
 
 
 
 
 
 
 
 
Tween 40 
Nonproprietary Names 
 Polysorbate 40 
Synonym 
 Crillet 2; E434; Eumulgin SMP; Glycosperse S-20; Hodag PSMP-20; 
Lamesorb SMP-20; Liposorb P-20; Lonzest SMP-20; Montanox 40; poly(oxy- 1,2-
ethanediyl) derivatives; Protasorb P-20; Ritabate 40; sorbitan monohexadecanoate; 
Sorbax PMP-20; Tween 40. 
Chemical name 
 Polyoxyethylene 20 sorbitan monopalmitate 
Structure 
 
 
Emprical formula and molecular weight 
 C62H122O26  
M.W: 1284 
Colour and form 
 Yellow oily liquid 
Solubility  
 Soluble in water and ethanol. Insoluble in mineral oils 
Safety 
LD50 (rat, IV): 1.58 g/kg. 
Moderately toxic by IV route. 
Tween 60 
Nonproprietary Names 
 Polysorbate 60 
Synonym 
 Atlas 70K; Atlas Armotan PMS 20; Capmul POE-S; Cremophor PS 60; 
Crillet3; Drewpone 60K; Durfax 60; Durfax 60K; E435; Emrite 6125; Eumulgin 
SMS; Glycosperse S-20; Glycosperse S-20FG; Glycosperse S-20FKG; Hodag PSMS-
20; Hodag SVS-18; Lamsorb SMS-20; Liposorb S-20; Liposorb S-20K; Lonzest 
SMS-20; Nikkol TS-10; Norfox SorboT-60 Montanox 60; Polycon T 60 K; 
polyoxyethylene 20 stearate; Ritabate 60; Protasorb S-20; Sorbax PMS-20; sorbitan 
monooctadecanoate poly(oxy-1,2-ethanediyl) derivatives; T-Maz 60; T-Max 60KHS; 
Tween 60; Tween 60K; Tween 60 VS. 
Chemical name 
 Polyoxyethylene 20 sorbitan monostearate 
Structure 
 
 
Emprical formula and molecular weight 
 C64H126O26  
M.W: 1312 
Colour and form 
 Yellow oily liquid 
Solubility  
 Soluble in water and ethanol. Insoluble in mineral oils 
Safety 
LD50 (rat, IV): 1.22 g/kg. 
 Moderately toxic by IV route. Experimental tumorigen; reproductive effects. 
 
Tween 80 
Nonproprietary Names 
 Polysorbate 80 
Synonym 
 Atlas E; Armotan PMO 20; Capmul POE-O; Cremophor PS 80; Crillet 4; 
Crillet 50; Drewmulse POE-SMO; Drewpone 80K; Durfax 80; Durfax 80K; E433; 
Emrite 6120; Eumulgin SMO; Glycosperse O-20; Hodag PSMO-20; Liposorb O-20; 
Liposorb O-20K; Montanox 80; polyoxyethylene 20 oleate; Protasorb O-20; Ritabate 
80; (Z)-sorbitan mono-9-octadecenoate poly(oxy1,2- ethanediyl) derivatives; Tego 
SMO 80; Tego SMO 80V; Tween 80. 
Chemical name 
 Polyoxyethylene 20 sorbitan monooleate 
Structure 
 
 
Emprical formula and molecular weight 
 C64H124O26  
M.W: 1310 
Colour and form 
 Yellow oily liquid 
Solubility  
 Soluble in water and ethanol. Insoluble in mineral oils 
Safety 
Moderately toxic by IV route. Mildly toxic by ingestion. Eye irritation. 
Experimental tumorigen, reproductive effects. Mutogenic data. 
· LD50 (mouse, IP): 7.6 g/kg 
· LD50 (mouse, IV): 4.5 g/kg 
· LD50 (mouse, oral): 25 g/kg 
· LD50 (rat, IP): 6.8 g/kg 
· LD50 (rat, IV): 1.8 g/kg 
 
Sorbitan Esters (Sorbitan Fatty Acid Esters) 11 
Functional Category 
Emulsifying agent; nonionic surfactant; solubilizing agent; wetting and 
dispersing/suspending agent. 
Applications in Pharmaceutical Formulation or Technology 
 Sorbitan monoesters are a series of mixtures of partial esters of sorbitol and its 
mono- and dianhydrides with fatty acids. Sorbitan diesters are a series of mixtures of 
partial esters of sorbitol and its monoanhydride with fatty acids. 
 Sorbitan esters are widely used in cosmetics, food products, and 
pharmaceutical formulations as lipophilic nonionic surfactants. They are mainly used 
in pharmaceutical formulations as emulsifying agents in the preparation of creams, 
emulsions, and ointments for topical application. When used alone, sorbitan esters 
produce stable water-in-oil emulsions and microemulsions but are frequently used in 
combination with varying proportions of a polysorbate to produce water-in-oil or oil-
in-water emulsions or creams of varying consistencies.  
Sorbitan monolaurate, sorbitan monopalmitate and sorbitan trioleate have also 
been used at concentrations of 0.01–0.05% w/v in the preparation of an emulsion for 
intramuscular administration. 
Stability and Storage Conditions 
Gradual soap formation occurs with strong acids or bases; sorbitan esters are 
stable in weak acids or bases.  Sorbitan esters should be stored in a well-closed 
container in a cool, dry place. 
 
Solubility 
 sorbitan esters are generally soluble or dispersible in oils; they are also soluble 
in most organic solvents. In water, although insoluble, they are generally dispersible. 
Safety 
Sorbitan esters are widely used in cosmetics, food products, and oral and 
topical 
pharmaceutical formulations and are generally regarded as nontoxic and nonirritant 
materials. However, there have been occasional reports of hypersensitive skin 
reactions following the topical application of products containing sorbitan esters. 
When heated to decomposition, the sorbitan esters emit acrid smoke and irritating 
fumes. The WHO has set an estimated acceptable daily intake of sorbitan 
monopalmitate, monostearate, and tristearate, and of sorbitan monolaurate and 
monooleate at up to 25 mg/kg body-weight calculated as total sorbitan esters. 
Regulatory Status 
Certain sorbitan esters are accepted as food additives in the UK. Sorbitan 
esters are included in the FDA Inactive Ingredients Guide (inhalations; IM injections; 
ophthalmic, oral, topical, and vaginal preparations). Sorbitan esters are used in 
nonparenteral medicines licensed in the UK. Sorbitan esters are included in the 
Canadian List of Acceptable Non-medicinal Ingredients 
 
 
 
 
 
 
 
Uses of Sorbitan Esters 
Uses Concentration (%) 
Emulsifying agent - 
Used alone in oil-in-water emulsions 1–15 
Used in combination with hydrophilic 
emulsifiers in oil-in-water 
emulsions 
1–10 
Used to increase the water-holding 
properties of ointments 
1–10 
Solubilizing agent - 
For poorly soluble active constituents in 
lipophilic bases 
1–10 
Wetting agent - 
For insoluble active constituents in 
lipophilic bases 
0.1–3 
Span 20 
 
Nonproprietary Names 
 Sorbitan monolaurate 
Synonym 
 Arlacel 20; Armotan ML; Crill 1; Dehymuls SML; E493; Glycomul L; Hodag 
SML; Liposorb L; Montane 20; Protachem SML; Sorbester P12; Sorbirol L; sorbitan  
laurate; Span 20; Tego SML. 
Chemical name 
 Sorbitan monododecanoate 
Structure 
 
 
Emprical formula and molecular weight 
 C18H34O6  
 M.W: 346 
Colour and form 
 Yellow viscous liquid 
Safety 
LD50 (rat, oral): 33.6 g/kg. 
Experimental neoplastigen. 
 
 
Span 40 
 
Nonproprietary Names 
 Sorbitan monopalmitate 
Synonym 
 1,4-Anhydro-D-glucitol, 6-hexadecanoate; Ablunol S-40; Arlacel 40; Armotan 
MP; Crill 2; Dehymuls SMP; E495; Glycomul P; Hodag SMP; Lamesorb SMP; 
Liposorb P; Montane 40; Nikkol SP-10; Nissan Nonion PP-40R; Protachem SMP; 
Proto-sorb SMP; Sorbester P16; Sorbirol P; sorbitan palmitate; Span 40. 
Chemical name 
 Sorbitan monohexadecanoate 
Structure 
 
Emprical formula and molecular weight 
 C22H42O6; M.W: 403 
Colour and form 
 Cream solid 
Span 60 
 
Nonproprietary Names 
 Sorbitan monostearate  
Synonym 
 Ablunol S-60; Alkamuls SMS; 1,4-Anhydro-D-glucitol, 6-octadecanoate; 
anhydrosorbitol monostearate; Arlacel 60; Armotan MS; Atlas 110K; Capmul S; Crill 
3; Dehymuls SMS; Drewmulse SMS; Drewsorb 60K; Durtan 6O; Durtan 60K; E491; 
Famodan MS Kosher; Glycomul S FG; Glycomul S KFG; Hodag SMS; Lamesorb 
SMS; Liposorb S; Liposorb SC; Liposorb S-K; Montane 60; Nissan Nonion SP-60R; 
Norfox Sorbo S- 60FG; Polycon S60K; Protachem SMS; Prote-sorb SMS; S-Maz 
60K; SMaz 60KHS; Sorbester P18; Sorbirol S; sorbitan stearate; Sorgen 50; Span 60; 
Span 60K; Span 60 VS; Tego SMS. 
Chemical name 
 Sorbitan mono-octadecanoate 
Structure 
 
Emprical formula and molecular weight 
 C24H46O6  
 M.W: 431 
Colour and form 
 Cream solid 
Safety 
LD50 (rat, oral): 31 g/kg. 
Very mildly toxic by ingestion. Experimental reproductive effects. 
Span 80 
 
Nonproprietary Names 
 Sorbitan monooleate  
Synonym 
 Ablunol S-80; Arlacel 80; Armotan MO; Capmul O; Crill 4; Crill 50; 
Dehymuls SMO; Drewmulse SMO; Drewsorb 80K; E494; Glycomul O; Hodag SMO; 
Lamesorb SMO; Liposorb O; Montane 80; Nikkol SO-10; Nissan Nonion OP-80R; 
Norfox Sorbo S-80; Polycon S80 K; Proto-sorb SMO; Protachem SMO; S-Maz 80K; 
Sorbester P17; Sorbirol O; sorbitan oleate; Sorgen 40; Sorgon S-40-H; Span 80; Tego 
SMO. 
Chemical name 
 (Z)-Sorbitan mono-9-octadecenoate 
Structure 
 
 
Emprical formula and molecular weight 
 C24H44O6 ; M.W:  429 
Colour and form : Yellow viscous liquid 
 
Dicetyl phosphate 
 
Synonym : Dihexadecyl phosphate 
Formula : C32H67O4P 
Molecular Weight : 546,85 g/mol 
Appearance 
Form solid 
Structure 
  
 
Toxicological Information 
Chronic exposure 
IARC: No component of this product present at levels greater than or equal to 0.1% is 
identified as 
probable, possible or confirmed human carcinogen by IARC. 
Potential Health Effects 
Inhalation May be harmful if inhaled. May cause respiratory tract irritation. 
Skin May be harmful if absorbed through skin. May cause skin irritation. 
Eyes May cause eye irritation. 
Ingestion May be harmful if swallowed 
Cholesterol 
Nonproprietary Names 
 Cholesterol 
Synonyms 
 Cholesterin; cholesterolum. 
Chemical Name 
 Cholest-5-en-β-ol [57-88-5] 
Empirical Formula and Molecular Weight 
 C27H46O  
 386.67 
 
 
Structure 
 
 
Functional Category 
Emollient; emulsifying agent. 
Applications in Pharmaceutical Formulation or Technology 
 Cholesterol is used in cosmetics and topical pharmaceutical formulations at 
concentrations of 0.3–5.0% w/w as an emulsifying agent. It imparts water-absorbing 
power to an ointment and has emollient activity. Cholesterol also has a physiological 
role. It is the major sterol of the higher animals, and it is found in all body tissues, 
especially in the brain and spinal cord. It is also the main constituent of gallstones. 
Description 
 Cholesterol occurs as white or faintly yellow, almost odorless, pearly leaflets, 
needles, powder, or granules. On prolonged exposure to light and air, cholesterol 
acquires a yellow to tan color. 
Stability and Storage Conditions 
 Cholesterol is stable and should be stored in a well-closed container, protected 
from light. 
Solubility  
Solvent Solubility 
Acetone Soluble 
Benzene 1 in 7 
Chloroform 1 in 4.5 
1 in 147 at 0°C 
1 in 78 at 20°C 
1 in 29 at 40°C 
1 in 19 at 50°C 
Ethanol 
1 in 13 at 60°C 
Ethanol (95%) 1 in 78 (slowly) 
 1 in 3.6 at 80°C 
Ether 1 in 2.8 
Isopropyl myristate 1 in 19 
Methanol 1 in 294 at 0°C 
Vegetable oils Soluble 
Water Practically insoluble 
 
 
Safety 
 Cholesterol is generally regarded as an essentially nontoxic and nonirritant 
material at the levels employed as an excipient. It has, however, exhibited 
experimental teratogenic and reproductive effects, and mutation data have been 
reported.Cholesterol is often derived from animal sources and this must be done in 
accordance with the regulations for human consumption. The risk of bovine 
spongiform encephalopathy (BSE) contamination has caused some concern over the 
use of animal-derived cholesterol in pharmaceutical products. However, synthetic 
methods of cholesterol manufacture have been developed. 
Regulatory Status 
 Included in the FDA Inactive Ingredients Guide (injections, ophthalmic, 
topical, and vaginal preparations). Included in nonparenteral medicines licensed in the 
UK. Included in the Canadian List of Acceptable Non-medicinal Ingredients. 
 
 
 
 
 
 
CHAPTER - V 
OBJECTIVES OF THE STUDY 
Salbutamol is a relatively selective beta-2-adrenoreceptor stimulant. After 
parenteral administration, stimulation of the beta receptors in the body, both beta-1 
and beta-2, occurs because (a) beta-2 selectivity is not absolute, and (b) higher 
concentrations of salbutamol occur in the regions of these receptors with parentral 
mode of administration. This results in the beta-1 effect of cardiac stimulation, and 
beta-2 effects of peripheral vasodilatation and hypotension, skeletal muscle tremor 
and uterine muscle relaxation.  
In order to reduce the uptake of salbutamol by beta-1 receptor and to increase the 
drug concentration in lungs with minimum dose through niosomes was tried in this 
study. 
• To formulate and optimize Salbutamol Sulphate niosomes for targeting lungs.  
• To reduce the dose level and dosing frequency of Salbutamol Sulphate by 
sustained release niosome formulation.  
• To determine the stability of Salbutamol Sulphate niosome formulation with 
and without stabilizing agent on storage. 
• To determine the stability of salbutamol sulphate niosomes as per ICH 
guidelines. 
• To compare the bio-distribution nature of niosomal formulation and drug in 
solution to different organs in mice when administered via intravenous route.   
• To evaluate the altered pharmacokinetics and metabolism of Salbutamol 
Sulphate niosomal formulation in rabbits. 
 
 
 
PLAN OF WORK 
1. Calibration of standard curve. 
2. Preformulation study and optimization of formulation with different ratios of 
non-ionic surfactants. 
3. Formulation of  Salbutamol Sulphate niosomes with different non-ionic 
surfactants like Tween 20, 40, 60, 80 and Span 20, 40, 60, 80 by thin film 
hydration technique using rotary flash evaporator. 
4. Characterization of Niosomes. 
a) Vesicle size determination of both empty and drug loaded formulations 
by optical microscopy. 
b) Photomicrographs using optical microscope to confirm lamellarity of 
vesicles before and after sonication of formulations. 
c) Surface morphology of vesicles by Scanning Electron Microscopy.  
d) Evaluation of osmotic shock of vesicles when incubated with three 
different medium.  
e) Viscosity determination using Ostwald viscometer.  
f) Determination of entrapment efficacy by ultra centrifugation 
technique. 
g) Determination of SPAN index.  
5. In vitro release of different formulations and drug in solution. 
6. Stability of Salbutamol Sulphate niosomes as per ICH guidelines.  
7. Tissue distribution nature of two best niosomal formulations and drug in 
solution using mice. 
8. Pharmacokinetic evaluation of Tween and Span niosomal formulations using 
rabbits. 
CHAPTER - VII 
Calibration of standard curve 
Preparation of Standard Stock Solution 
 Accurately, about 100 mg of Salbutamol Sulphate was weighed and 
transferred to a 100 ml volumetric flask. The drug was dissolved in 100 ml of PBS pH 
7.4 with shaking and then the volume made up to the mark with PBS pH 7.4 to obtain 
a standard stock solution of a drug concentration, 1000 µg/ml.  
Selection of Analytical Wavelength 
 With appropriate dilution of the standard stock solution with PBS pH 7.4, the 
solution was scanned using the double beam UV visible spectrophotometer (Model: 
UV- 1650 PC, SHIMADZU) in the spectrum mode between the wavelength range of 
400 nm to 200 nm. The λmax of Salbutamol Sulphate was found to 276 nm, which was 
selected as the analytical wavelength for further analysis. (Fig 1) 
Standard Plot 
Stock solution was further diluted to get the different concentrations to 
determine the linearity range. Linearity was obtained in the concentration between 20 
- 200 µg/ml. The standard samples were analyzed at 276 nm using UV 
Spectrophotometer.  (Table1 & Fig 2) 
 
 
 
 
 
 
 
 
 
 Table 1: Calibration of standard Curve 
 
S.No Concentration (µg/ml) Absorbance at 276 nm 
1 20 0.13049 
2 40 0.22803 
3 60 0.34167 
4 80 0.45667 
5 100 0.55981 
6 120 0.65942 
7 140 0.77563 
8 160 0.87244 
9 180 0.98254 
10 200 1.10425 
 
Fig 1: Spectrum report 
 
 
 
 
 Fig 2: Calibration of standard curve 
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Straight line equation: y = 0.00542x + 0.01312 
Correlation co-efficient: r2 = 0.99957 
 
Preformulation study and optimization of Formulation 
 Formulations were optimized by taking different micro molar ratios of Tween 
80 and keeping cholesterol in a constant ratio i.e. 20 µM (Table 2). 20:90 µM 
(cholesterol: Tween 80) ratio gives the spherical vesicle of niosomes. With this ratio 
formulations were tried with different non-ionic surfactants such as Tween (20, 40 & 
60) and Span (20, 40, 60 & 80) by thin film hydration technique. Vesicles were found 
to be spherical in all the formulations. Thus 20:90 µM ratio of cholesterol and non-
ionic surfactant respectively was taken for the further development of formulations.  
 
 
Table 2: Optimization of formulation 
 Preparation of Niosomes 
Thin film hydration technique 
20 µM of cholesterol, 90 µM of Non Ionic surfactant were dissolved in 800 ml 
of round bottom flask with 10 ml of chloroform and it was allowed to rotate in a flash 
evaporator at 60oC. Vacuum was applied at 620 mmHg from vacuum pump for one 
hour. The flask was   allowed to rotate 125 rpm for 1 hour to get a dry film. Film was 
hydrated with 5 ml of Phosphate Buffer Saline pH 7.4 containing 8 mg of Salbutamol 
Sulphate and it was allowed to rotate for 60 min. The same procedure was carried out 
with different non ionic surfactants. All the formulations were sonicated for 2 minutes 
using Bath sonicator.  
 
 
Cholesterol : Surfactant (Tween 80) 
S.No 
Ratio (µM) Weight (mg) 
Result 
1 20 : 30 7.6:39.3 Spherical vesicles not seen 
2 20 : 50 7.6:65.5 Spherical vesicles not seen 
3 20 : 60 7.6:78.6 Spherical vesicles not seen 
4 20 : 70 7.6:91.7 Spherical vesicles with crystals 
5 20: 90 7.6:117.9 Spherical vesicles 
6 20 : 120 7.6:157.2 Spherical vesicles with crystals 
Formulations were also tried without the addition of stabilizing agent 
cholesterol and also with the inclusion of charge inducing agent dicetyl phosphate 
(DCP). Niosome vesicles were also formulated without the addition of drug in order 
to determine any changes in vesicle size after the addition of drug. Formulation 
identity was shown in table 3. 
Quantities of surfactant, cholesterol and DCP used in the formulations were 
given in table 4. 
 
Table 3: Formulation identity 
 
 
S.No Code Surfactant used 
1 F1 Tween 20 
2 F2 Tween 40 
3 F3 Tween 60 
4 F4 Tween 80 
5 F5 Span 20 
6 F6 Span 40 
7 F7 Span 60 
8 F8 Span 80 
9 F9 Tween 40 without cholesterol 
10 F10 Tween 60 without cholesterol 
11 F11 Span 40 without cholesterol 
12 F12 Span 60 without cholesterol 
13 F13 Span 60 +cholesterol + DCP 
 
 
 
 
 
 
 
 
Table 4: Quantities of different variables used in formulation 
 
 
S.No Code Amount of surfactant (mg) 
Amount of 
cholesterol (mg) 
Amount of 
DCP (mg) 
1 F1 101.5 7.7 - 
2 F2 115.5 7.7 - 
3 F3 118.1 7.7 - 
4 F4 117.9 7.7 - 
5 F5 31.4 7.7 - 
6 F6 36.3 7.7 - 
7 F7 38.8 7.7 - 
8 F8 38.6 7.7 - 
9 F9 115.5 7.7 - 
10 F10 118.1 7.7 - 
11 F11 36.3 7.7 - 
12 F12 38.8 7.7 - 
13 F13 38.8 7.7 2.7 
 
 
 
 
 
 
 Characterization of niosomes 
a. Vesicle size determination 
 Vesicle size of unsonicated formulation was determined by optical microscopy 
using a pre calibrated eye piece. Eye piece was calibrated using stage micrometer at 
40 X magnification. Size of each division of eye piece micrometer was determined 
using the formula 
        Number of divisions of stage micrometer 
Size of each division = --------------------------------------------------------     X 10 
                 Number of divisions of eye piece micrometer 
 
 Each division of eye piece micrometer was found to be 2 µm at 40 X 
magnification.  
 The average size of 50 vesicles was counted for 3 times at different time 
intervals after 4 hours of the formulation (Table 5).  
b. Photomicrographs37 
A drop niosomal suspension was placed on the microscopic glass slide. 
Photographs of sonicated and unsonicated formulations were taken at 40 X 
magnification using the digital camera (Olympus 8 Mega pixel) attached to the eye 
piece of the microscope. Shape and lamellar nature of the unsonicated vesicles was 
confirmed with the photographs. (Fig 3 to Fig 18) 
 
 
 
 
 
 
  
 
 
Table 5: Vesicle size determination 
 
S.No Code Empty formulation (µm) 
Formulation with 
drug (µm) 
1 F1(Tween 20 + CHOL) < 2 3.04 
2 F2(Tween 40 + CHOL) < 2 3.62 
3 F3(Tween 60 + CHOL) < 2 2.75 
4 F4(Tween 80 + CHOL) < 2 2.37 
5 F5(Span 20 + CHOL) 2.44 4.12 
6 F6(Span 40 + CHOL) 2.36 3.58 
7 F7(Span 60 + CHOL) 2.16 3.12 
8 F8(Span 80 + CHOL) 2.04 2.50 
9 F9(Tween 40) < 2 3.91 
10 F10(Tween 60) < 2 2.91 
11 F11(Span 40) 4.32 5.25 
12 F12(Span 60) 4.18 4.75 
13 F13(Span 60 + CHOL+DCP) 2.84 2.95 
 
 
 
 
 
 
  
 
Fig 3: F1 unsonicated        Fig 4:  F1 sonicated  
(Tween 20 +CHOL)                                                      (Tween 20 +CHOL) 
 
 
 
 
 
 
 
 
 
 
     
 
Fig 5: F2 unsonicated               Fig 6:  F2 sonicated 
(Tween 40 +CHOL)                                                      (Tween 40 +CHOL) 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 7: F3 unsonicated                   Fig 8:  F3 sonicated 
(Tween 60 +CHOL)                                                      (Tween 60 +CHOL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 9: F4 unsonicated                    Fig 10:  F4 sonicated 
(Tween 80 +CHOL)                                                      (Tween 80 +CHOL) 
 
  
 
 
 
 
 
 
 
 
 
 
Fig 11: F5 unsonicated                Fig 12:  F5 sonicated 
(Span 20 +CHOL)                                                      (Span 20 +CHOL) 
 
 
  
 
 
 
 
 
 
 
 
 
 
Fig 13: F6 unsonicated                Fig 14:  F6 sonicated 
(Span 40 +CHOL)                                                      (Span 40 +CHOL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 15: F7 unsonicated                Fig 16:  F7 sonicated 
(Span 60 +CHOL)                                                      (Span 60 +CHOL) 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 17: F8 unsonicated                Fig 18:  F8 sonicated 
(Span 80 +CHOL)                                                      (Span 80 +CHOL) 
 
 
 
 
 
 
 
 
 
 
 
 c. Scanning Electron Microscopy 
 Vesicles were viewed and photographed by Scanning electron microscopy in 
order to determine the surface characteristics of the formulated vesicles. 100 µ litres 
of the samples were mounted on the metal stub and allowed to dry at 20 o C. The dried 
sample was coated with platinum for 30 seconds with the thickness of 20 mA(10-3) 
using JEOL JF1600 Auto fine coater. Then the sample was viewed and captured 
under 500X resolution by secondary electron detector using JEOL JSM –F, Field 
emission scanning electron microscopy at a voltage of 3.0 kV. (Fig 19) 
 
Fig 19: SEM Image 
 
 
 
 
  
d. Osmotic Shock27,44 
 The effect of osmotic sensitivity and aggregation tendency was studied on 
niosomal formulations with and without cholesterol. The effect of osmotic change 
was investigated by monitoring the change in vesicle diameter following the 
incubation of the vesicular suspension in medium of different tonicity. A hypertonic 
media was simulated using 1 M NaI solution, normal saline with 0.9% NaCl and 
hypotonic media with 0.5% NaCl. The vesicular suspension was incubated in these 
media for 3 h following which the change in vesicle size was measured. This helped 
in determining the effect of osmotic shock on the prepared MLVs with and without 
cholesterol. (Table 6) 
  
 
Table 6: Effect of osmotic shock on niosomal formulation  
 
S.No Code 
Average size of 
formulation 
(µm) 
Average 
size  in 
hypotonic 
solution 
(µm) 
Average 
size  in 
saline 
solution 
(µm) 
Average size  
in 
hypertonic 
solution 
(µm) 
1 F1(Tween 20 + CHOL) 3.0 3.6 3.4 Shrinked 
2 F2(Tween 40 + CHOL) 3.6 4.0 3.8 Shrinked 
3 F3(Tween 60 + CHOL) 2.7 3.0 2.8 Shrinked 
4 F4(Tween 80 + CHOL) 2.3 2.6 2.4 Shrinked 
5 F5(Span 20 + CHOL) 4.1 4.6 4.2 Shrinked 
6 F6(Span 40 + CHOL) 3.5 4.2 3.6 Shrinked 
7 F7(Span 60 + CHOL) 3.1 3.8 3.4 Shrinked 
8 F8(Span 80 + CHOL) 2.5 3.6 3.2 Shrinked 
9 F9(Tween 40) 3.9 4.8 4.2 Shrinked 
10 F10(Tween60) 2.9 4.9 4.4 Shrinked 
11 F11(Span 40) 5.2 6.9 5.7 Shrinked 
12 F12(Span 60) 4.7 6.5 5.2 Shrinked 
13 F13(Span 60 + CHOL+DCP) 2.9 3.9 3.18 Shrinked 
 
* Hypertonic solution – 1 M Sodium Iodide (NaI) 
* Hypotonic solution – 0.5 % Sodium Chloride 
* Saline solution - 0.9% sodium Chloride 
 
 
 
 e. Determination of viscosity41 
 Density was determined using specific gravity bottle. The weight of water and 
formulations were substituted in the formula and the density was calculated. 
                     w2 
 Density of sample (d2) =   ------- X d1 
                w1   
  
Where,  
 w1 – weight of water  
 w2 – weight of sample 
 d1 – density of water (0.998) 
 d2 – density of sample 
 Viscosity of the formulations was determined using Ostwald viscometer. The 
time taken for water and formulations to flow from point A to B was calculated and 
substituted in the formula and the viscosity was calculated (Table 7).  
 
          ρ1 x t1  
 Viscosity of sample (η1) = ---------- X η2 
           ρ2 x t2 
Where,  
 ρ1 – density of sample 
 ρ2 – density of water 
 η1 – viscosity of sample 
 η2 – viscosity of water 
 t1 – time taken to sample to flow from point A to B 
 t2 – time taken to water to flow from point A to B 
 
   
  
Table 7: Determination of viscosity 
S.No Code Viscosity (centipoise) 
1 F1(Tween 20 + CHOL) 2.052 
2 F2(Tween 40 + CHOL) 2.072 
3 F3(Tween 60 + CHOL) 2.121 
4 F4(Tween 80 + CHOL) 1.80 
5 F5(Span 20 + CHOL) 3.269 
6 F6(Span 40 + CHOL) 2.56 
7 F7(Span 60 + CHOL) 1.839 
8 F8(Span 80 + CHOL) 2.936 
9 F9(Tween 40) 2.311 
10 F10(Tween 60) 2.065 
11 F11(Span 40) 4.826 
12 F12(Span 60) 4.059 
13 F13(Span 60 + CHOL+DCP) 1.928 
14 Drug in solution 0.9349 
 
f. Determination of entrapment efficacy25 
 One ml of the formulation was taken and ultra centrifuged at 13, 000 rpm 
(15700 X g) at 4o C for 90 minutes using eppendorf centrifuge (model 5415 R, Fig- 
20). The supernatant was recovered using micro pipette and analyzed by UV method 
for Salbutamol sulphate content. The percentage of drug encapsulation (EP (%)) was 
calculated by the following equation. (Table 8) 
 
EP (%) = [(Ct - Cr)/Ct] X 100 
Where,  
 Ct – Concentration of total Salbutamol Sulphate. 
 Cr – Concentration of free drug in supernatant solution. 
 
 
Fig 20: Eppendorf centrifuge 
 
 
 
 
 
 
 
 
 
 
 
 
Table 8: Percentage entrapment efficacy 
S.No Code Entrapment efficacy (%) 
1 F1(Tween 20 + CHOL) 81.4 
2 F2(Tween 40 + CHOL) 86.9 
3 F3(Tween 60 + CHOL) 89.6 
4 F4(Tween 80 + CHOL) 79.2 
5 F5(Span 20 + CHOL) 87.7 
6 F6(Span 40 + CHOL) 90.0 
7 F7(Span 60 + CHOL) 90.5 
8 F8(Span 80 + CHOL) 77.7 
9 F9(Tween 40) 64.8 
10 F10(Tween 60) 69.2 
11 F11(Span 40) 76.1 
12 F12(Span 60) 78.4 
13 F13(Span 60 + CHOL+DCP) 89.6 
 g. Determination of polydispersity (SPAN) index12 
 Polydispersity or SPAN index is used to determine the narrow size distribution 
of the vesicle size. Standard deviation of the vesicle size was determined and the 
width of the vesicle size distribution was given by a SPAN index which was 
calculated by the following equation. The cumulative percentage size distribution of 
different formulations is depicted in fig 21 and fig 22 and the SPAN index is shown in 
table 9.  
SPAN index = (D0.9 – D0.1)/D0.5 
Where,  
 D0.9 – particle diameter determined at 90th percentile of particle undersized 
 D0.1 - particle diameter determined at 10th percentile of particle undersized 
 D0.5 - particle diameter determined at 50th percentile of particle undersized 
      
Table 9: SPAN Index 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
S.No Code SPAN index 
1 F1 1.18 
2 F2 1.11 
3 F3 1.62 
4 F4 2.16 
5 F5 1.45 
6 F6 1.50 
7 F7 1.84 
8 F8 2.14 
9 F9 0.758 
10 F10 1.77 
11 F11 1.56 
12 F12 0.97 
13 F13 2.0 
 
 
 
Fig 21: Cumulative % size distribution (Tween formulations) 
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Fig 22: Cumulative % size distribution (Span formulations) 
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5. In vitro release studies55 
 In vitro release was carried out using Himedia dialysis membrane 50 with the 
molecular weight cut-off ranges from 12000 – 14000 daltons which has the capacity 
of holding 1.61 ml/cm. Dialysis bag which acts as a donor compartment was soaked 
in warm water for 10 minutes and Himedia closure clips are used to close dialysis bag 
on both the sides to prevent the leakage of formulation during the release study (Fig 
23, Fig 24 and Fig 25). 
 The niosomal formulations were centrifuged at 13, 000 rpm for 90 minutes at 
4o C. The sediment which has the entrapped drug was taken for the release study after 
reconstituted with 1 ml of PBS pH 7.4. The dispersed entrapped drug was taken in the 
dialysis bag and it closed using closure clips. Dialysis bag was placed in 100 ml of 
PBS pH 7.4 which acts as a receptor compartment. The medium was stirred by using 
the magnetic stirrer at 100 rpm in room temperature. At each one hour interval 5 ml of 
samples were withdrawn and after each withdrawn same volume of medium was 
replaced. Then the samples were assayed spectrophotometrically, at 276 nm using 
PBS pH 7.4 as blank. Release data of Tween 20, 40, 60 & 80 formulations were 
shown in table 10 - table 15 and fig 26, Span 20, 40, 60 & 80 in table 16 – 22 and fig 
27. The releases of all formulations were compared with pure Salbutamol sulphate 
solution. Drug in solution data was shown in table 23. 
 
 
 
 
 
 
 
 
 
 
 
 
   Fig 23: Dialysis membrane                Fig 24: Closure clips             
 
 
 
 
Fig 25: In vitro release set-up 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Table 10: Release data for formulation F1 (Tween 20 + CHOL) 
 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.02601 2.378229 0.002378 0.237823 13.43632 
2 0.03345 3.750923 0.003751 0.375092 21.19165 
3 0.04016 4.98893 0.004989 0.498893 28.18604 
4 0.05103 6.994465 0.006994 0.699446 39.51675 
5 0.05969 8.592251 0.008592 0.859225 48.54379 
6 0.0625 9.110701 0.009111 0.91107 51.47289 
7 0.06335 9.267528 0.009268 0.926753 52.35891 
8 0.06653 9.854244 0.009854 0.985424 55.67369 
9 0.07092 10.66421 0.010664 1.066421 60.24976 
12 0.09253 14.65129 0.014651 1.465129 82.77566 
 
 
Table 11: Release data for formulation F2 (Tween 40 + CHOL) 
 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.02637 2.444649 0.002445 0.244465 12.93465 
2 0.02686 2.535055 0.002535 0.253506 13.41299 
3 0.03589 4.201107 0.004201 0.420111 22.22808 
4 0.03833 4.651292 0.004651 0.465129 24.61001 
5 0.05493 7.714022 0.007714 0.771402 40.81493 
6 0.05774 8.232472 0.008232 0.823247 43.55805 
7 0.07629 11.65498 0.011655 1.165498 61.66657 
8 0.08911 14.0203 0.01402 1.40203 74.18146 
9 0.09192 14.53875 0.014539 1.453875 76.92458 
12 0.09643 15.37085 0.015371 1.537085 81.32724 
 
  
Table 12: Release data for formulation F3 (Tween 60 + CHOL) 
 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.01831 0.957565 0.000958 0.095756 4.910588 
2 0.01941 1.160517 0.001161 0.116052 5.951367 
3 0.02076 1.409594 0.00141 0.140959 7.228688 
4 0.02173 1.588561 0.001589 0.158856 8.146466 
5 0.02612 2.398524 0.002399 0.239852 12.30012 
6 0.02948 3.01845 0.003018 0.301845 15.47923 
7 0.03216 3.512915 0.003513 0.351292 18.01495 
8 0.03357 3.773063 0.003773 0.377306 19.34904 
9 0.0376 4.516605 0.004517 0.451661 23.16208 
12 0.07628 11.65314 0.011653 1.165314 59.75967 
 
 
Table 13: Release data for formulation F4 (Tween 80 + CHOL) [n=2] 
 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.02808 2.760148 0.00276 0.276015 16.04±0.82 
2 0.02502 2.195572 0.002196 0.219557 12.76±2.36 
3 0.03149 3.389299 0.003389 0.33893 19.70±1.34 
4 0.03268 3.608856 0.003609 0.360886 20.98±1.02 
5 0.03479 3.998155 0.003998 0.399815 23.24±0.98 
6 0.04211 5.348708 0.005349 0.534871 31.09±1.32 
7 0.05396 7.535055 0.007535 0.753506 43.80±1.28 
8 0.06478 9.531365 0.009531 0.953137 55.41±1.24 
9 0.07316 11.07749 0.011077 1.107749 64.40±0.86 
12 0.09342 14.8155 0.014815 1.48155 86.13±0.32 
 
 Table 14: Release data for formulation F9 (Tween 40) 
 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.0193 1.140221 0.00114 0.114022 8.086677 
2 0.01611 0.551661 0.000552 0.055166 3.912486 
3 0.01892 1.070111 0.00107 0.107011 7.589438 
4 0.02087 1.429889 0.00143 0.142989 10.14106 
5 0.03162 3.413284 0.003413 0.341328 24.20769 
6 0.0321 3.501845 0.003502 0.350185 24.83578 
7 0.0564 7.98524 0.007985 0.798524 56.63291 
8 0.05713 8.119926 0.00812 0.811993 57.58813 
9 0.05811 8.300738 0.008301 0.830074 58.87048 
12 0.06616 9.785978 0.009786 0.978598 69.4041 
 
Table 15: Release data for formulation F10 (Tween 60) 
 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.01976 1.225092 0.001225 0.122509 8.167282 
2 0.02016 1.298893 0.001299 0.129889 8.659287 
3 0.02563 2.308118 0.002308 0.230812 15.38745 
4 0.03162 3.413284 0.003413 0.341328 22.75523 
5 0.04089 5.123616 0.005124 0.512362 34.15744 
6 0.04504 5.889299 0.005889 0.58893 39.26199 
7 0.06494 9.560886 0.009561 0.956089 63.73924 
 
 
  
 
 
 
 
 
Fig 26: Comparative In vitro release profile of Tween formulations 
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Table 16: Release data for formulation F5 (Span 20 + CHOL) 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.03003 3.119926 0.00312 0.311993 16.33469 
2 0.03105 3.308118 0.003308 0.330812 17.31999 
3 0.03918 4.808118 0.004808 0.480812 25.17339 
4 0.04316 5.542435 0.005542 0.554244 29.01799 
5 0.04792 6.420664 0.006421 0.642066 33.61604 
6 0.05326 7.405904 0.007406 0.74059 38.77437 
7 0.05796 8.273063 0.008273 0.827306 43.31446 
8 0.06327 9.252768 0.009253 0.925277 48.44381 
9 0.06247 9.105166 0.009105 0.910517 47.67103 
12 0.08327 12.9428 0.012943 1.29428 67.76337 
 
Table 17: Release data for formulation F6 (Span 40 + CHOL) 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.03088 3.276753 0.003277 0.327675 16.71813 
2 0.03254 3.583026 0.003583 0.358303 18.28074 
3 0.03293 3.654982 0.003655 0.365498 18.64787 
4 0.04749 6.341328 0.006341 0.634133 32.35372 
5 0.05216 7.202952 0.007203 0.720295 36.74976 
6 0.05432 7.601476 0.007601 0.760148 38.78304 
7 0.05976 8.605166 0.008605 0.860517 43.90391 
8 0.06794 10.11439 0.010114 1.011439 51.60404 
9 0.06462 9.501845 0.009502 0.950185 48.4788 
12 0.08674 13.58303 0.013583 1.358303 69.30115 
Table 18: Release data for formulation F7 (Span 60 + CHOL) 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.01354 0.077491 0.0000775 0.00775 0.393401 
2 0.01536 0.413284 0.000413 0.041328 2.097889 
3 0.02384 1.97786 0.001978 0.197786 10.0399 
4 0.02936 2.99631 0.002996 0.299631 15.2097 
5 0.03369 3.795203 0.003795 0.37952 19.26499 
6 0.03906 4.785978 0.004786 0.478598 24.2943 
7 0.04218 5.361624 0.005362 0.536162 27.21636 
8 0.05429 7.595941 0.007596 0.759594 38.55808 
9 0.06392 9.372694 0.009373 0.937269 47.57713 
12 0.07324 11.09225 0.011092 1.109225 56.30584 
 
 
Table 19: Release data for formulation F8 (Span 80 + CHOL) 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.01929 1.138376 0.001138 0.113838 6.735955 
2 0.02466 2.129151 0.002129 0.212915 12.59853 
3 0.02612 2.398524 0.002399 0.239852 14.19245 
4 0.02661 2.48893 0.002489 0.248893 14.7274 
5 0.0271 2.579336 0.002579 0.257934 15.26234 
6 0.03857 4.695572 0.004696 0.469557 27.78445 
7 0.04384 5.667897 0.005668 0.56679 33.53785 
8 0.05469 7.669742 0.00767 0.766974 45.38309 
9 0.06125 8.880074 0.00888 0.888007 52.54482 
12 0.07218 10.89668 0.010897 1.089668 64.47739 
 
Table 20: Release data for formulation F11 (Span 40) 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.01526 0.394834 0.000395 0.039483 2.378518 
2 0.0199 1.250923 0.001251 0.125092 7.535678 
3 0.0304 3.188192 0.003188 0.318819 19.20598 
4 0.03052 3.210332 0.00321 0.321033 19.33935 
5 0.03198 3.479705 0.00348 0.34797 20.96208 
6 0.03772 4.538745 0.004539 0.453875 27.34184 
7 0.04226 5.376384 0.005376 0.537638 32.38785 
8 0.05957 8.570111 0.00857 0.857011 51.62717 
 
 
Table 21: Release data for formulation F12 (Span 60) 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.04016 4.98893 0.004989 0.498893 29.17503 
2 0.0542 7.579336 0.007579 0.757934 44.3236 
3 0.05457 7.647601 0.007648 0.76476 44.72282 
4 0.06042 8.726937 0.008727 0.872694 51.03472 
5 0.06299 9.201107 0.009201 0.920111 53.80764 
6 0.06873 10.26015 0.01026 1.026015 60.00086 
7 0.07764 11.90406 0.011904 1.190406 69.61438 
8 0.08643 13.52583 0.013526 1.352583 79.09842 
 
 
Table 22: Release data for formulation F13 (Span 60 + DCP) 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.03246 3.56826568 0.003568 0.356827 18.29±1.64 
2 0.04443 5.77675277 0.005777 0.577675 29.62±1.86 
3 0.07648 11.6900369 0.01169 1.169004 59.94±2.42 
4 0.09412 14.9446494 0.014945 1.494465 76.63±1.38 
5 0.10059 16.1383764 0.016138 1.613838 82.76±0.66 
6 0.10291 16.5664207 0.016566 1.656642 84.95±0.52 
7 0.10437 16.8357934 0.016836 1.683579 86.33±0.62 
8 0.10535 17.0166052 0.017017 1.701661 87.26±0.48 
9 0.09842 15.7380074 0.015738 1.573801 80.70±2.14 
12 0.10732 17.3800738 0.01738 1.738007 89.12±1.36 
 
 
Table 23: Release data for drug in solution 
Time in 
hours Absorbance 
Concentration 
in µg/ml 
Concentration 
in mg/ml 
Total 
concentration 
(mg) 
Cumulative 
percentage 
release 
1 0.04304 5.520295 0.00552 0.55203 28.30921 
2 0.06049 8.739852 0.00874 0.873985 44.81976 
3 0.08492 13.24723 0.013247 1.324723 67.93453 
4 0.10096 16.20664 0.016207 1.620664 83.11098 
5 0.11682 19.13284 0.019133 1.913284 98.11714 
 
  
 
 
 
 
Fig 27: Comparative In vitro release profile of Span formulations and drug in 
solution 
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Determination of drug release kinetics   
 Drug release kinetic models such as Higuchi, Peppas, Zero order and First 
order were predicted for two best formulations from in vitro data’s. The regression 
coefficient and slope values were determined (fig 28– fig 35). 
 
    Fig 28 
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 Fig 29 
PEPPAS PLOT OF F4 (Tween 80+Chol)
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Regression = 0.988186 
Slope = 0.112851 
 
 
Fig 30 
ZERO ORDER RELEASE-F4 (Tween 80+Chol)
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Fig 31 
FIRST ORDER RELEASE-F4 (Tween 80+Chol)
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Regression = 0.95614
Regression = 0.96379 
  
Fig 32 
HIGUCHI PLOT OF F13(Span 60+DCP)
0
10
20
30
40
50
60
70
80
90
100
0 1 2 3 4
Square root of time (min)
C
um
ul
at
iv
e 
pe
rc
en
ta
ge
 d
ru
g 
re
le
as
e(
%
)
 
 
 
Fig 33 
PEPPAS PLOT OF F13 (Span 60+DCP)
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Regression = 0.991141 
Slope = 0.642019 
     Fig 34 
ZERO ORDER RELEASE-F13(Span 60+DCP)
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Fig 35 
FIRST ORDER RELEASE-F13(Span 60+DCP)
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Regression = 0.97087 
Regression = 0.98366 
6. Stability studies36  
Stability study was carried out at accelerated condition as per ICH guidelines 
with slight modification. Two ml of each formulation was taken in a 10 ml ampoule, 
sealed and kept at room temperature. Relative humidity of atmosphere was noted each 
day and it was found to be 65 ± 5% during study period. Formulations with 
cholesterol was studied for 90 days and formulations without cholesterol was studied 
for 60 days. 
Parameters to be analyzed during storage 
Turbidity, colour, pH, leakage rate and vesicle size 
In accelerated condition, the products are usually stored up to 3 months. The sampling 
is done at short intervals of 15, 30, 60 and 90 days after storage.  
 The collected samples were subjected to analysis for above said parameters. 
a. Colour 
 The change in colour of the formulations was visually analyzed by keeping the 
sample at the dark background (fig 36 and fig 37).  
b. Turbidity  
 Percentage transmittance was analyzed to determine the turbidity nature of the 
formulation with different non-ionic surfactants. 100 µ litres of niosomes formulations 
were taken and diluted with PBS pH 7.4 in order to reduce the lipid concentration. 
After rapid mixing for 5 minutes, the percentage transmittance was measured as the 
absorbance at 276 nm with an ultraviolet – visible spectrophotometer. Higher the 
percentage transmittance shows less turbid the nature of formulation (table 24).  
 
 
 
 
c. pH  
 pH changes on storage was measured using LABINDIA µp controlled pH 
analyser at each period interval (table 25). 
d. Drug leakage from vesicles 
 Drug leakage from vesicles on accelerated storage condition was determined 
by analyzing the supernatant solution after ultra centrifugation at 13, 000 rpm for 90 
minutes at 4o C. Percentage of drug remaining vesicles were shown in table 26.     
e. Vesicle size 
 Changes in the vesicle size on storage were determined at 40 X magnification 
using optical microscopy with pre-calibrated eye piece micrometer (table 27).  
                      
 Fig 36: Colour observed in Tween formulations 
 
  
   
 
 
 
 
 
 
 
 
 
 
                         Fig 37: Colour observed in Span formulations 
 
 Table 24: % Transmittance on accelerated storage condition 
S.No Code First day After 15 days 
After 30 
days 
After 60 
days 
After 90 
days 
1 F1 89.49 89.46 89.16 89.24 89.02 
2 F2 92.22 91.78 91.64 91.62 91.36 
3 F3 92.93 90.94 90.94 91.28 91.14 
4 F4 92.16 88.37 88.46 90.32 90.28 
5 F5 88.78 85.64 84.72 85.34 84.97 
6 F6 90.43 86.96 87.02 89.42 89.24 
7 F7 84.96 81.48 81.46 83.27 82.92 
8 F8 89.83 86.14 85.89 87.74 87.53 
9 F9 81.24 80.94 - - - 
10 F10 82.16 81.56 - - - 
11 F11 94.28 94.12 94.08 94.10 - 
12 F12 92.64 92.38 92.26 92.24 - 
13 F13 36.36 35.41 34.96 34.82 - 
 
Table 25: pH on accelerated storage condition 
S.No Code First day After 15 days 
After 30 
days 
After 60 
days 
After 90 
days 
1 F1 7.41 7.32 7.26 7.24 7.26 
2 F2 7.08 6.98 6.96 7.02 7.00 
3 F3 6.94 6.92 6.94 6.90 6.84 
4 F4 7.15 7.01 7.12 7.06 6.98 
5 F5 7.44 7.22 7.18 7.24 7.14 
6 F6 7.33 7.16 7.10 7.12 7.16 
7 F7 7.41 7.24 7.16 7.20 7.18 
8 F8 7.19 7.08 7.01 7.0 6.92 
9 F9 7.12 7.06 - - - 
10 F10 6.96 6.84 - - - 
11 F11 7.29 7.21 7.24 7.20 - 
12 F12 7.48 7.32 7.30 7.24 - 
13 F13 7.24 7.16 7.14 7.10 - 
 
 
Table 26: Percentage drug remaining (leakage) in vesicles on accelerated storage 
condition 
S.No Code First day After 15 days 
After 30 
days 
After 60 
days 
After 90 
days 
1 F1 81.4 75.2 72.4 63.3 59.4 
2 F2 86.9 79.6 76.9 64.8 60.9 
3 F3 89.6 80.4 84.2 71.3 67.4 
4 F4 79.2 71.9 66.1 57.8 54.3 
5 F5 87.7 81.2 76.9 64.3 59.9 
6 F6 90.5 82.6 78.9 71.2 67.3 
7 F7 90.0 83.4 79.6 72.6 68.4 
8 F8 77.7 70.7 64.2 57.8 54.7 
9 F9 64.8 61.2 - - - 
10 F10 69.2 64.6 - - - 
11 F11 76.1 72.3 68.2 61.6 - 
12 F12 78.4 73.8 69.1 61.8 - 
13 F13 89.6 87.2 84.8 82.7 - 
 
Table 27: Vesicles size (µm) variations on accelerated storage condition 
S.No Code First day After 15 days 
After 30 
days 
After 60 
days 
After 90 
days 
1 F1 3.04 3.21 3.26 3.20 3.25 
2 F2 3.62 3.73 3.82 3.62 3.60 
3 F3 2.75 2.92 3.12 3.00 3.15 
4 F4 2.37 2.68 4.16 4.10 4.15 
5 F5 4.12 4.31 4.42 4.32 4.3 
6 F6 3.58 3.40 3.48 3.34 3.35 
7 F7 3.12 3.36 3.41 3.26 3.25 
8 F8 2.50 2.76 2.97 2.90 2.90 
9 F9 3.91 4.12 - - - 
10 F10 2.91 3.24 - - - 
11 F11 5.25 5.48 5.64 5.5 - 
12 F12 4.75 4.88 5.02 5.15 - 
13 F13 2.95 3.28 3.42 3.4 - 
 
 
7. Tissue distribution studies32, 49 
 Two best formulations were selected from the in vitro release data and the 
tissue distribution nature was compared with the drug in solution after administered to 
mice through intravenous route. Animal ethical committee clearance obtained from 
PSGIMSR (Registration number: 158/1999/CPCSEA; dated on 5th January 2009).  
 Male mice with weight of 20 – 25 g were divided in to 4 groups comprising of 
3 animals each to carryout tissue distribution profile. Animal dose was calculated 
from human dose according to the animal body surface area with respect to weight of 
the animal53.  Salbutamol sulphate equivalent to 50 – 55 µg were dosed intravenously 
via the tail vein with formulations. Group 1 receives formulation F4 (Tween 80 + 
CHOL), group 2 receives formulation F13 (Span 60 + CHOL + DCP), group 3 
receives drug in solution and group 4 was treated as control (fig 38). 
 One hour after the injection of the drug, mice were sacrificed after placing in 
tank containing anesthetic ether dipped cotton swab. Blood was collected by cardiac 
puncture into tubes containing 30 µl of 10 % trisodium citrate. Plasma was separated 
from other blood components by centrifugation at 3000 rpm for 20 minutes and it was 
stored below zero degree temperature. Different organs like heart, lungs, liver, spleen 
and kidney were removed from each and washed with PBS pH 7.4 (fig 39). 
 The organs were homogenized with 4 ml of PBS pH 7.4 using tissue 
homogenizer and it was ultra centrifuged at 13, 000 rpm for 30 minutes. Then the 
clear supernatant was separated and kept at refrigerator until analysis.   
 
 
 
 
Drug concentration in different organs and plasma were analyzed by HPLC 
technique. Drug was extracted from plasma and other organs by liquid-liquid 
extraction technique using ethyl acetate as solvent.  
 
Calibration of standard curve 
 Accurately, about 10 mg of Salbutamol Sulphate was weighed and transferred 
to a 10 ml standard flask. The drug was dissolved in 5 ml of PBS pH 7.4 with shaking 
and then the volume was made up to the mark with PBS pH 7.4. Drug in stock 
solution was extracted with equal volume of ethyl acetate with vigorous shaking. 
Then the mixture was allowed to separate and the organic layer was completely 
evaporated at 100o C. Then the residue was reconstituted with 10 ml of buffer which 
is considered as the standard stock solution containing 1000 µg/ml. 
From the stock solution further dilutions was made to get different 
concentrations. Linearity was obtained in the concentration between 50 - 150 µg/ml. 
The standard samples were analyzed at 276 nm using HPLC with 
acetonitrle:water:glacial acetic acid:triethyl amine (55:45:01:0.1) as mobile phase. 
Retention time was found to be 4.2 minutes. Then the standard graph was plotted 
against concentration vs area (fig 40). 
Analysis of samples 
100 µl of plasma was taken and to this 1 ml of ethyl acetate was added, mixed 
well for 5 min and kept aside for 15 min for the separation of organic layer. The 
organic layer was separated using micropipette and allowed to evaporate at 100o C to 
get the residue. The residue was then reconsituted with 1 ml of PBS pH 7.4. Buffer 
solutions were then injected into 250 x 4.6 mm, phenomenex Luna C18(2) 100-A 
column and eluted with an acetonitrle:water:glacial acetic acid:triethyl amine 
(55:45:01:0.1) mobile phase. The peak area was determined at 276 nm.        
 Drug present in the supernatant layer obtained from different organs (fig 39) 
was extracted with equal volume of ethyl acetate and analysis was performed as 
described above (Table 28 - Table 30).  
 The area obtained from the analysis of different organs was calibrated using 
the standard curve. Chromatogram was shown in fig 41 – fig 43. 
 Drug distributed in different organs were calculated using the area 
obtained from the HPLC analysis. Comparative drug distribution profile was shown in 
Fig 44.  
Comparison between the drug distribution in lungs  for Formulation F4 
(Tween 80+Chol) , Formulation F13 (Span 60+DCP+Chol) and drug in solution was 
performed by analysis of variance (one way ANOVA with Turkey’s multiple 
comparison post test) with graph pad prism (version 3.0)software.  
 
Fig 38: Formulation administering through tail vein 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 39: Different organs isolated from injected mice 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 40: HPLC Calibration curve  
 
 
 
 
 
 
Table 28: Distribution of drug in different organs for F4 (Tween 80 + CHOL) [n=3] 
 Table 29: Distribution of drug in different organs for F4 (Span 60 + CHOL + DCP) [n=3] 
Organs Area Concentration in µg/ml 
Total 
concentration in 
2 ml 
% of drug 
in organs 
LUNGS 9501 1.38305349 2.766107 4.19±0.34 
LIVER 10359 1.43091426 2.861829 4.33±0.6 
SPLEEN 18055 1.86021086 3.720422 5.63±0.9 
KIDNEY 8505 1.32749484 2.65499 4.02±0.76 
HEART 14505 1.66218553 3.324371 5.03±0.7 
PLASMA 113325 7.17454119 14.34908 21.74±1.8 
 
Table 30: Distribution of drug in different organs for drug in solution [n=3] 
Organs Area Concentration in µg/ml 
Total 
concentration 
in 2 ml 
% of drug in 
organs 
LUNGS 15587 1.72254142 3.445083 4.64±0.46 
LIVER 44725 3.34791097 6.695822 9.02±0.7 
SPLEEN 0 0 0 0 
KIDNEY 0 0 0 0 
HEART 33766 2.73659843 5.473197 7.37±1.4 
PLASMA 12133 1.52987114 3.059742 4.12±0.92 
Organs Area Concentration in µg/ml 
Total 
concentration 
in 5 ml 
% of drug 
in organs 
LUNGS 21238 2.03776427 10.18882 14.17±0.83 
LIVER 8162 1.30836169 6.541808 9.09±0.9 
SPLEEN 10144 1.41892118 7.094606 9.86±1.2 
KIDNEY 23292 2.15234005 10.7617 14.96±1.4 
HEART 15771 1.73280527 8.664026 12.05±0.3 
PLASMA 19240 1.92631227 9.631561 13.39±1.36 
 
 
 
 
Fig 41: Chromatogram for F4 (Tween 80 + CHOL) formulation 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 42: Chromatogram for F13 (Span 60 + CHOL + DCP) formulation 
 
 
 
 
 
 
 
Fig 43: Chromatogram for drug in solution 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Fig 44: Comparative drug distribution in different organs and plasma 
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 Pharmacokinetic evaluation 
 Pharmacokinetic evaluation was done using rabbits in order to determine the 
kinetics of Tween, Span with DCP niosomal formulations and drug in solution. 
Rabbits weighing around 1.5 to 2.0 kg were divided in to 3 groups each containing 3 
animals. Drug equivalent to 1.12 – 1.5 mg was administered. Group 1 receives 
formulation F4 (Tween 80 + CHOL), group 2 receives formulation F13 (Span 60 + 
CHOL + DCP) and group 3 receives drug in solution. Drug was administered 
intravenously through ear vein. 0.5 ml of the blood was collected into the tubes 
containing 30 µl of 10 % trisodium citrate through ear vein puncture. Blood samples 
was collected every 30 minutes time interval up to 2 hours and every 1 hour interval 
up to 5 hours from the time of injection (fig 45). 
  
Fig 45: Blood sample collection from ear vein 
 
 
 
 
 
 
 
 
 The collected blood samples were centrifuged at 3000 rpm for 20 min to 
separate the plasma. 100 µ litre of the plasma samples was taken and treated with 
ethyl acetate for extracting the drug from plasma. Organic layer separated and allowed 
to dry at 100o C. The residue was then reconstituted with 1 ml of PBS pH 7.4 and 
analysed using HPLC as said in tissue distribution studies.  
 Concentration of the drug was calculated and the parameters such as 
maximum concentration (Cmax), time maximum to reach maximum concentration 
(Tmax), rate of elimination (Kel), half-life (t1/2), area under the curve (AUC), area 
under the first moment curve (AUMC) and mean residence time (MRT) were 
determined using the formulas 54. Data’s were given in table 31.       
  
Table 31: Pharmacokinetic data’s 
 
Results 
S.No Parameter 
F4 (Tween 80+CHOL) F13 (Span 60+CHOL+DCP) 
1 Cmax 3.36 µg/ml 2.36 µg/ml 
2 Tmax 1 hr 1 hr 
3 Kel 1.99 hrs-1 0.621 hrs-1 
4 t1/2 0.35 hrs 1.1 hrs 
5 AUC0-t* 3.82 µg. hr/ml 4.98 µg. hr/ml 
6 AUC0*-α 4.44 µg. hr/ml 7.76 µg. hr/ml 
7 AUMC 0-t* 10.76 µg. hr2/ml 4.291 µg. hr2/ml 
8 AUMC0*-α 12.63 µg. hr2/ml 17.139 µg. hr2/ml 
9 MRT 2.84 hrs 2.2 hrs 
 
 
CHAPTER - VII 
RESULT AND DISCUSSION 
Selection of analytical wavelength & calibration of standard curve 
 The diluted stock solution was scanned for λmax and it was found to be 276 nm 
(fig 1). In standard graph linearity was obtained between 20-200 µg/ml concentration 
of Salbutamol Sulphate and the regression value was found to be r2=0.99957 
Preformulation and optimization of formulation 
 According to some reports (S.Baskaran et al., 2001; Himanshu M. Varshney et 
al., 2007) non-ionic surfactant can form bilayer vesicles in the ratio of 1:1 
(CHOL:Surfactant). 
 We found that the thin film of cholesterol and surfactant in the ratio 1:1 did 
not form vesicles with Salbutamol Sulphate. Table 2 shows the vesicle formation 
nature of different ratios of Non-ionic surfactant Tween 80. 20:90 µ molar ratio of 
cholesterol:Tween 80 shows the spherical vesicle formation without any crystals and 
found to be stable more than 150 days on refrigerated condition. 
Preparation of niosomes 
 Niosomes were prepared by thin film hydration technique. Formulations were 
made with and without the addition of cholesterol. It was also confirmed that non-
ionic surfactants (Tween and Span) are capable of forming vesicles any concentration 
without the addition of cholesterol. 
 Formulation was also tried with the addition of drug to the cholesterol and 
non-ionic surfactant which is dissolved in the chloroform. Since Salbutamol Sulphate 
is insoluble in chloroform which leads to the distribution of drug particles throughout 
the thin film layer of cholesterol and surfactant mixture. On hydration it shows no 
proper vesicle formation. This result states that, drugs which are freely soluble in 
water can be dissolved in hydration medium for the better vesicle formation. 
  Vesicle size, photomicrographs and SEM 
 M. Marconi et al., (2002), studied the influence of the loaded drug on vesicle 
size. Both empty and drug loaded vesicles shows difference in the vesicle size. 
 In our study, drug loaded vesicles was found to be bigger in size (table 5) 
when compared to empty vesicles. This confirms that the drug has been incorporated 
into vesicular system.  
 The vesicle size in the formulations without cholesterol was bigger size when 
compared to formulations with cholesterol (table 5). It may be due to the 
accommodation of cholesterol in the molecular cavities of the surfactant. Inclusion of 
DCP has not increased the vesicle size significantly. 
 Gopi N. Devaraj (2002) reported that cholesterol alters the fluidity of chain in 
bilayer of non-ionic surfactants and abolishes the bilayer and surface pressure of 
surfactants/cholesterol mixture thereby causes decrease in the vesicle size.     
 Vesicle size was found to be greater in span formulations when compared to 
Tween. 
 Vesicles seen through optical microscopy were photographed using Olympus 
8 mega pixel camera. It proves that   thin film hydration technique results in the multi-
lamellar vesicles (fig 15). 
 Bath sonication was carried out for 2 minutes. Multi-lamellar vesicles get 
converted to uni-lamellar vesicles which make the vesicle size less than a micron.  
 SEM shows the spherical nature of the vesicles. The size was found to be more 
than 10 µm (Fig 19). It shows much variation with the vesicle size with respect to size 
determined through optical microscopy (table 5). The difference may be due to the 
aggregation of vesicles while drying at 20o C before coating with platinum. The loss 
of water molecules in the vesicles leads to the aggregation with the adjacent vesicles 
and forms bigger vesicles. 
Osmotic shock 
 The addition of KI in the formulation containing DCP causes shrinkage due to 
the K+ counter ion interaction with the negative charge of DCP (D. Gopinath et al., 
2004). But in our study it was observed that the formulation with DCP as well without 
DCP shows shrinkage in vesicles when incubated with KI at 37o C. It proves that, 
shrinkage of vesicles was not due to the interaction of K+ ion with negative charge in 
DCP. 
 In the formulations without cholesterol vesicles was found to be low in 
number when compared to formulation with cholesterol on incubation with hypertonic 
medium (KI). After 3 hours of incubation, the vesicles found to disappear in 
formulations without cholesterol. This confirms the membrane stabilizing nature of 
cholesterol. 
 Formulations incubated with 0.9% NaCl (Saline) shows no much vesicle 
difference (Table 7). It indicated that, the niosomal formulations can be very well 
diluted with normal saline for the parentral use. 
 Formulations incubated with 0.5% NaCl (Hypotonic medium) shows higher 
increase in vesicle size when compared to formulation incubated at normal saline 
(table7). Vesicle size difference of formulation without cholesterol, incubated in 
hypotonic medium was found to be higher when compared to formulations with 
cholesterol. This result further confirms the stabilizing nature of cholesterol. 
 
 
Viscosity 
 Presence of cholesterol in the formulation shows difference in the viscosity. 
Formulations with cholesterol found to be less viscous when compared to 
formulations without cholesterol (Table 8). 
 Tween 60 viscosity was found to be high and turbidity is low. Span 60 has less 
viscosity showing more turbidity. This shows that high viscosity reduces the fusion or 
aggregation of vesicles during storage thereby producing minimal turbidity. The other 
Tween and Span shows no correlation between the viscosity and turbidity.  
Entrapment efficacy 
 Entrapment efficacy was found to high in span 60 formulation.  In both Tween 
and Span formulations, surfactant containing stearate fatty acid entraps more amount 
of drug when compared to surfactant containg Oleate fatty acid. 
In Span formulations, entrapment was low in least HLB value (Span 80; HLB 
- 4.3) surfactant and at the same time the highest HLB value (Span 80, HLB – 8.6; 
Span 40, HLB – 6.7) surfactant entraps less amounts of drug. This result explains that 
the highest and lowest lipophillic nature of Span does not show good entrapment but 
the intermediate lipophillicity (Span 60, HLB – 4.7) confirms the best entrapment of 
drug (table 8). 
Our results was also similar to M.Manconi et al., (2002) in which Sorbitan 
monostearate (C18) always shows the high entrapment efficiency with respect to other 
formulations.  
In Tween formulations, surfactant with low HLB value (Tween 60, HLB – 
14.9) shows best entrapment when compared with high HLB value surfactants 
(Tween 20, HLB – 16.7; Tween 40, HLB – 15.6; Tween 80, HLB – 15.0)  
 
SPAN Index 
 Size distribution profile is shown in table 10. Small SPAN indicates a narrow 
size distribution. Formulation F9 (Tween 40) and F12 (Span 60) shows minimum 
SPAN value which confirms the uniform size distribution of vesicles. 
In vitro release 
 In vitro release from pure drug shows release for 5 hours but the formulations 
with cholesterol extends the drug release upto 12 hours (Fig 26 and Fig27). 
 Tween and Span formulations with cholesterol shows release upto 12 hours 
but the formulations without cholesterol has a release of 7-9 hours (fig 26 and fig 27). 
This may be due to the adsorption of drug in the lipophillic region of niosomes. Hence 
during in vitro release with dialysis membrane, the adsorbed drug comes out fastly 
moreover the amount of drug released is also very low (50 – 79 %) in the 
formulations without cholesterol and high (upto 86 %) in formulations with 
cholesterol (fig 26 and fig 27). This result confirms that, presence of cholesterol in the 
bilayer alters the rate of release of Salbutamol Sulphate.  
Span 60 formulation with DCP shows 89% of drug release which is higher 
than the span 60 formulation without DCP (fig 27). Thus presence of DCP in the 
formulation also alters the release of drug.  
 Eventhough the Span 60 formulation has greater entrapment efficiency, Tween 
80 formulation shows maximum amount of drug release. It may be due to the fatty 
acid chain length difference in the polyoxy ethylene sorbitan esters. The maximum 
release in Tween 80 may be due to the presence of unsaturated alkyl chain. In Tween 
formulations it was conformed that higher the alkyl chain length of surfactant shows 
lesser the release. The release from Tween formulations can be ranked has Tween 80 
> Tween 20 > Tween 40 > Tween 60 which is having the alkyl chain length of C9=9, 
C12, C16, C18  respectively (fig 26). The unsaturated bond present in the Tween 80 
increases the fluidity & permeability of the drug.  
 The release from Span formulations can be ranked as Span 40 > Span 20 > 
Span 80 > Span 60. It shows no correlation between the alkyl chain length and release 
of drug.    
Drug release kinetics 
 Drug release kinetics was derived for two best formulations from the in vitro 
profile. Result from Higuchi plot shows that both Tween 80 and Span 60 formulation 
follows diffusion mechanism where the regression value was above 0.95 (fig 28 and 
fig 33)  
 Slope value for formulation F4 (Tween 80 + CHOL) from Peppas plot was 
found to be less than 0.5 (Slope - 0.112; fig 29), which confirms that formulation F4 
follows Fickain’s diffusion mechanism. But in formulation F13 (Span 60 + DCP), the 
value was above 0.5 (Slope - 0.642; fig 33) which confirms Non-Fickian diffusion 
mechanism.  
 Regression value of zero order and First order kinetics for both formulations 
were above 0.9 (fig 30, fig 31, fig 34 & fig 35). Thus it was confirmed that both 
formulations follow mixed order release kinetics.    
Stability Studies 
 Stability of niosomes was evaluated for all the formulations. No change in 
colour was observed on 90 days storage at room temperature (approximately 28 ± 3o 
C; RH – 65 ± 5 %)(fig 36 & fig 37).  
 J.Y. Fung et al., (2001), reported that the presence of DCP shows higher 
turbidity value due to the high degree of hydrophilicity & also increase in the vesicle 
size. 
 In our study also, inclusion of DCP shows higher turbid value & increase in 
the vesicle size (Table 24). 
 Stability result states that cholesterol also increases the turbidity of the 
formulations. There is no much difference in the turbidity value of the formulations 
during storage (table 24). 
There is no much difference in the pH was observed during storage (table 25). 
 Drug leakage from vesicles was observed in all the formulations. Leakage was 
associated with the increase in vesicle size (table 26 & table 27). Leakage was found 
to be more in formulations without cholesterol (table 26).  
These results confirm that formulations are not stable on accelerated storage 
and it should be stored only in refrigerated condition.     
 Bath sonicated vesicles were kept for stability assessment. The result obtained 
on 15th day shows that vesicles are in micron range (table 27) which can be measured 
using optical microscopy. It confirms that, formulation on storage leads to the 
aggregation of vesicles. This shows that bath sonication for 2 min converts multi-
lamellar vesicles to uni-lamellar vesicles for a shorter period only. 
 After 30 days storage, vesicles was disappeared in Tween formulations 
without cholesterol but the Span formulation without cholesterol was found to be 
stable up to 60 days (table 27). 
Gradual increase in the vesicle size associated with leakage of drug from 
vesicles was observed. The formulation without cholesterol shows more increase in 
size when compared to formulations with cholesterol and drug leakage was higher in 
formulations without cholesterol (Table 27).  
  Vesicle size was found to be increasing up to 60 days and 90th day result 
shows that no much difference in size when compared previous data. This shows that 
aggregation of vesicles occurs up to certain period of time. 
Tissue distribution studies 
 Tissue distribution of drug in organs was compared for formulations and drug 
in solution. Formulation F4 (Tween 80 + Chol) shows three folds increase in drug 
distribution to lungs   (table 28 – table 30) when compared to Formulation F13 (Span 
60 + DCP) and drug in solution.  In formulation F4 (Tween 80 + Chol), drug reaching 
to liver was less than the amount of drug distributed in lungs. Thus the metabolite 
product of salbutamol sulphate i.e. inactive 4’-O-sulphate, will be minimum in 
niosomal formulation. 
 In formulation F4 (Tween 80 + Chol), uptake of salbutamol sulpahte by β1 
receptor was less than that of the lungs. But the formulation containing span 60 + 
DCP and drug in solution shows more distribution of drug in heart with that of lungs 
(fig 44). Thus it can be concluded that the undesirable effects produced by the 
stimulation of β1 receptor can be reduced in niosomal formulations. Drug in plasma 
was found to be higher in Span 60 when compared to Tween 80 formulation and drug 
in solution.    
 Formulation F4 (Tween 80 + CHOL) show better distribution to specific 
organs when compared to drug in solution. This confirms the targeting nature of the 
niosomal formulation. 
Pharmacokinetic studies 
 Kinetics between the F4 (Tween 80 + Chol) and F13 (Span 60 + DCP) 
formulations were determined. Drug in solution injected to rabbit via IV route does 
not show any concentration of salbutamol sulphate after 30 minutes. It may due to the 
rapid excretion of drug when given through IV. Even though the excretion was found 
to be high, niosomal formulation shows drug concentration in plasma upto 90 minutes      
(table 31). Maximum concentration was found in F4 (Tween 80 + Chol) formulation. 
Even the concentration is high, the half life was found to be very low in F4 when 
compared to F13. Rate of elimination was found to be less in Span 60+DCP 
formulation.  
 From the data’s (table 31) obtained from pharmacokinetic studies it was 
proved that the concentration and mean residence time is more for Tween 
80+Cholesterol formulation and also the distribution of drug was more in F4 (Tween 
80+Chol) formulation.  
 Level of significance of Tween 80 Vs Span 60 formulation, Tween 80 Vs 
Drug in solution and Span 60 Vs Solution was found to be p<0.001, p<0.001 and 
p>0.05 respectively. The value shows that formulation F4 (Tween 80 + CHOL) was 
found to be the best. 
 
CONCLUSION 
 
Stable noisome formulation were prepared by thin film hydration technique 
using Tween 20, 40, 60, 80 and Span 20, 40, 60, 80 in the ratio of 20:90 
(cholesterol:surfactant). Drug entrapment was found to be high in Span 60 and Tween 
60 formulations. Good in vitro release was found to be in Tween 80+CHOL and Span 
60+DCP+CHOL formulations. Tween 80 formulation shows three fold increased drug 
concentration in lungs and found to have higher plasma concentration as well as mean 
residence time.  
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